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Abstract: Background: Traditional Chinese Medicine (TCM) with its focus on herbal use is popular
and appreciated worldwide with increased tendency, although its therapeutic efficacy is poorly
established for most herbal TCM products. Treatment was perceived as fairly safe but discussions
emerged more recently as to whether herb induced liver injury (HILI) from herbal TCM is a
major issue; Methods: To analyze clinical and case characteristics of HILI caused by herbal TCM,
we undertook a selective literature search in the PubMed database with the search items Traditional
Chinese Medicine, TCM, alone and combined with the terms herbal hepatotoxicity or herb induced
liver injury; Results: HILI caused by herbal TCM is rare and similarly to drugs can be caused by an
unpredictable idiosyncratic or a predictable intrinsic reaction. Clinical features of liver injury from
herbal TCM products are variable, and specific diagnostic biomarkers such as microsomal epoxide
hydrolase, pyrrole-protein adducts, metabolomics, and microRNAs are available for only a few TCM
herbs. The diagnosis is ascertained if alternative causes are validly excluded and causality levels of
probable or highly probable are achieved applying the liver specific RUCAM (Roussel Uclaf Causality
Assessment Method) as the most commonly used diagnostic tool worldwide. Case evaluation
may be confounded by inappropriate or lacking causality assessment, poor herbal product quality,
insufficiently documented cases, and failing to exclude alternative causes such as infections by
hepatotropic viruses including hepatitis E virus infections; Conclusion: Suspected cases of liver
injury from herbal TCM represent major challenges that deserve special clinical and regulatory
attention to improve the quality of case evaluations and ascertain patients’ safety and benefit.
Keywords: Traditional Chinese Medicine; herbal TCM hepatotoxicity; diagnostic biomarkers;
RUCAM; pyrrolizidine alkaloids; HLA; microsomal epoxide hydrolase; pyrrole-protein adducts;
metabolomics; microRNA
1. Introduction
The reputation of herbal Traditional Chinese Medicine (TCM) has substantially improved within
the past few years [1–3]. This was achieved through efforts closing up its gaps with modern medicine [4,5],
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considering clinical aspects [6–15], as well as researching and developing new drugs [16–18]. The Nobel
Prize for Medicine or Physiology 2015 will certainly further inspire modern TCM research in the near
future, although the Nobel Prize committee did not specify that the prize was for TCM [19]. Instead, the
2015 Nobel Prize was awarded to Youyou Tu for her pioneering work in drug development originating
from herbal TCM and her discovery of artemisinin for the treatment of malaria [19,20]. Artemisinin is
derived from the herbal TCM Qing Hao (Artemisia annua L.), known for more than two thousand
years as a Chinese herbal medicine for various ailments [19–23]. The initial breakthrough in the
discovery of artemisinin dates back to 4 October 1991, when an extract derived from Artemisia annua
was found to be 100% effective against parasitemia in mice infected with Plasmodium berghei and in
monkeys with Plasmodium cynomolgi [22]. After ascertaining that the extract was safe for human use,
clinical efficacy was tested in the Chinese Hainan province in trials with patients infected with both
Plasmodium vivax and Plasmodium falciparum [22]. The results were encouraging: patients treated with
the extract experienced rapid disappearance of symptoms such as fever and decrease of parasitemia,
whereas patients receiving chloroquine did not. Artemisinin and its derivatives such as artesunate
and arthemeter are now successfully used to treat patients with malaria by Plasmodium vivax or
Plasmodium falciparum, preferring a combination with antimalarial drugs other than artemisinin, called
artemisinin-based combination therapies (ACTs), and banning artemisinin-based monotherapy that
may promote the risk of antimalarial drug resistance [23]. Malaria is transmitted among humans
by female mosquitoes of the Anopheles genus, which take blood meals from patients with malaria
to carry out egg production; such blood meals are the link between the human and the mosquito
hosts in the parasite life circle and enable the transfer of malaria through infected mosquitos by biting
humans [24]. Based on treatment with ACTs together with other approaches such as use of insecticides
and insecticide-treated mosquito nets, the WHO stated that the number of patients with malaria and
malaria-related mortality has been drastically reduced within recent years [23], and there is no question
that most of this improvement is attributable the work of Youyou Tu with Artemisia annua.
From discovering the TCM herb Artemisia annua and the active molecule to developing the
beneficial drug was a long but successful process in drug research and development [22]. This is not in
line with mainstream philosophy of herbal TCM that prefers the use of a bundle of herbs rather than to
focus on a single herb or even a single molecule [25,26], as opposed to what Youyou Tu did [22]. In 1996,
she started her project against malaria by investigating more than 2000 Chinese herbal preparations
and identified 640 hits that had possible antimalarial properties. More than 380 extracts obtained from
around 200 herbs were evaluated, and a high antimalarial activity was found in an extract derived
from Artemisia annua as prepared according to “A Handbook of Prescriptions for Emergencies” by Ge
Hong (from 248 to 346 AD). Originating from artemisinin with a molecular weight of 282 Da and a
molecular formula of C15H22O5, dihydroartemisinin was found to be more stable and 10 times more
effective than artemisinin, and adding a hydroxyl group to the molecule provided more opportunities
for developing new artemisinin derivatives through esterification [22]. The fascinating route from
a TCM herb via a molecule to a drug is finally highlighted again at the molecular level, now in the
human erythrocytes infected with plasmodia [20]. The molecular basis of treatment efficacy includes
among several mechanisms the cleavage of artemisinin’s endoperoxide bridge by a Fe(II) Fenton,
which is facilitated by heme–iron originating from hemoglobin degradation in the parasites’ food
vacuoles [20,27]. Autodigestion of plasmodium food vacuoles is achieved following their damage by
hydroxyl radicals and superoxide anions [20]. Consequently, artemisinin with its derivatives is a drug
with a specific molecular target in a specific parasitic disease [20,27]; toxicity has not been found in
clinical studies with normal doses [27]. Expectations are high that more hidden drug champions can be
derived from herbal TCM with high efficacy and little harm, providing a favorable benefit-risk profile.
As opposed to artemisinin and its derivatives, which lack proven hepatotoxic adverse reactions,
there is major clinical concern that the use of various TCM herbs or herbal products may be associated
with the risk of toxic liver disease [7,28,29]. Herb induced liver injury (HILI) from herbal TCM may
be severe and rarely leads to acute liver failure (ALF), which is often life-threatening unless liver
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transplantation is performed. These serious clinical courses are a particular challenge for clinicians
caring for these patients with suspected HILI, considering that the indication of therapy is often vague.
In this review article, we focus on potential hepatotoxic TCM herbs and will discuss typical clinical
features of HILI cases, considering also specific TCM herbs with specific types of liver injury. We will
analyze the issue of specific diagnostic biomarkers and valid causality assessment, providing evidence
that is best achieved by the use of the liver specific RUCAM (Roussel Uclaf Causality Assessment
Method) or positive results from unintentional reexposure. Finally, confounding variables will be
discussed as well as clinical and regulatory strategies to minimize the risk of hepatotoxicity in patients
treated with TCM herbs.
2. Data Sources and Searches
2.1. Search Terms
We searched the PubMed database to identify publications such as case reports, case series, and
review articles for the following terms: Herbal TCM or herbal Traditional Chinese Medicine; both terms
were combined with hepatotoxicity or liver injury. This allowed the identification of publications of
hepatotoxicity combined with herbal TCM or herbal Traditional Chinese Medicine, which provided
hits of around 27,100 or 98,000; for liver injury combined with herbal TCM or Traditional Chinese
Medicine, 1,320,000 or 1,970,000 hits were presented. These figures indicate a high internet presence
for the chosen search terms. The first 100 hits of publications in each category were usually considered.
In addition, we used our large and actualized personal scientific archives, which contain original
full-length publications relating to the search terms, covering the years from 1983 to early 2016.
2.2. Data Extraction
Prior to our analysis, the publications were assessed regarding their scientific and clinical quality,
appropriateness and relevance for the topic of this article. Publications of good quality were preferred
and considered for evaluation. The focus of our search was on publications in the English language,
but few reports in other languages were also considered if they were of significant clinical importance
and added to present knowledge. The literature search was limited since many reports of HILI from
herbal TCM were in the Chinese language without an English abstract. Consequently, these Chinese
publications were outside the focus of our present review article. Publications were also manually
searched for additional publications not yet identified. The literature search ended on 15 April 2016.
Given the large number of publications of liver injury by TCM herbs, not all reports could be selected.
Attempts were made to search for the most relevant publications for analysis and inclusion in the
reference list of this review.
3. Herbal Traditional Chinese Medicine, Its History, Philosophy and Challenges
3.1. History
TCM herbs and Indian herbal Ayurvedic medicine are among the few ancient medicines that
have survived many other medicine cultures around the world. Since two thousand years, numerous
herbal formulas were widely used in China for the treatment of various minor ailments and diseases.
The TCM philosophy and its associated herbal TCM created curiosity and skepticism in Western
countries, since transparency is only partially provided [6,10]. Ancient medical books are historical
examples for this broad empirical knowledge. Among these are formulas for 52 diseases (Wu Shi er
Bing Fang, second century BC), Yellow Emperor’s Canon of Internal Medicine (Huang Di Nei Jing,
Later Han from 25 to 220 AD), and Prescription from the Golden Chamber (Shang Han Lun and Jin Gui
Yao Lue, from 200 BC to 200 AD) [30–32]. For some years, Chinese intellectuals, scientists, physicians,
and politicians have shown a clear preference towards the rational Western science and medicine [33].
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However, only in 2007, the Chinese Government represented by the Chinese Ministry of Science
and Technology invited politicians and experts from 50 countries to draft the Beijing Declaration
on Traditional Chinese Medicine (TCM) and classified TCM as part of biomedicine [33]. The future
of TCM was seen in the unification of historical Chinese and modern Western medicine, based on
molecular biological legitimation [33]. Part of the Chinese government would obviously favor a
rigorous modernization of herbal TCM that can be used to effectively treat human diseases.
3.2. Philosophical Background
To understand the principles of herbal TCM therapy, some information of the philosophical
background may be helpful for those not familiar with these interesting but challenging TCM
concepts [6,10]. In short, core elements of the TCM philosophy are ideas primarily related to “yin
and yang”, two opposing yet complementary forces; disease results from an imbalance of these
forces [6]. Philosophical support is provided by the “Five Phases” as the interaction among the
five elements: wood, earth, water, fire and metal [6]. To meet the requirements of herbal therapy
according to TCM philosophy, herbal TCM products are commonly blends of four to six different
herbs [28]. This approach allows for disease treatment via different molecular disease targets.
As opposed to modern Western medicine with clear diagnostic criteria as a prerequisite for
treatment indication, such conditions are mostly vague or even missing in the context of herbal TCM
diagnosis and treatment [9,10]. As an example, treatment protocol of herbal TCM is established based
on a syndrome differentiation. Clinical signs and symptoms are clustered around uniquely ‘Chinese’
nosological categories and diagnostic terms, such as stagnation of meridians, liver-Qi stagnation, blood
stasis, dampness, and others [34]. The doctor as specialist for TCM takes a detailed history of physical
and vegetative symptoms, augmented by information gained through somatic signs. Based on this
“phenomenological evaluation”, he arrives at a so-called “energetic diagnosis” that is based on the
conceptual framework of TCM. For instance, rheumatoid arthritis shows so-called syndrome patterns
of “wind-cold-damp”, “heat-toxicity”, or “wind-damp-hot” [35–37]. For conditions such as these,
specific herbal TCM products are available [38–40].
3.3. Herbal TCM Use and Current Issues
Herbal TCM presents potentially great perspectives with special challenges related to its
expanding worldwide use, its integration into modern Western medicine, and the approaches it
offers in the research and development of new drugs [1–12]. A variety of reports and analyses focused
on important issues related to the use of herbal TCM [8–10,41–53]. In particular, its integration into
modern Western medicine will not easily be accomplished due to differences in philosophy and
approaches of diagnoses and therapy. In addition, TCM philosophy requires that a TCM physician is
involved in the treatment, who will not always be available for consumers who order TCM herbals via
the internet.
Apart from these uncertainties, however, impressive data are reported for China, where the use
of herbal TCM represents around 40% of all health care services [7]. In addition, the worldwide use
of herbal TCM is well recognized, but robust quantitative results are not available. This lack is due
to insufficient definitions of consumer cohorts or the heterogeneity of both herbal product groups
and treatment modalities. For instance, in many reports on traditional medicine, traditional herbal
medicine, natural medicine, and complementary and alternative medicine (CAM), there is a mix of
various treatments including herbal TCM which is often not separately mentioned and discussed.
A similar problem relates to reports on general TCM, which may include practices unrelated to herbal
TCM such as acupuncture, moxibustion (burning a herb above the skin to apply heat to acupuncture
points), Tui Na (Chinese therapeutic massage), dietary therapy, or Tai Chi (shadow boxing) and Qi
Gong (practices that combine specific movements or postures, coordinated breathing, and mental
focus) [6].
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At least according to publications on clinical trials performed in mainland China, the focus of
TCM is here clearly on herbal remedies (90.3%), followed by acupuncture (4.4%), massage (3.8%),
moxibustion (1.2%), Qi Gong (0.1%), and other therapies (0.2%) [42]. Despite these accurate figures
in China, a realistic impression on the quantitative use of herbal TCM in other countries requires
a more sophisticated analytical approach, also to quantify the worldwide consumption of herbal
TCM products. Of note, in other Asian countries, TCM became popular and is called for instance
“Traditional Asian Medicine” (TAM) or “Traditional Occidental Medicine” (TOM), and in Japan also
Kampo medicine [53]. The basic principles of TCM are identical or vary only a little between countries;
hence, TCM as the overarching term is warranted and used in this review article in order to facilitate
the discussions on the major TCM related issues.
Current issues of concern are listed with proposals as to how these problems can be solved to
provide effective and safe herbal TCM medicine also in Western countries to those individuals who
prefer this specific therapy instead of conventional medicines (Table 1).
Table 1. Herbal TCM and related issues of concern.
Issues Details of Issues and Proposed Solutions First Author
‚ Efficacy
Therapeutic efficacy is rarely provided for most TCM herbs.
Randomized controlled trials (RCTs) are urgently needed, based on
criteria of evidence based medicine (EBM).
Manheimer, 2009 [9]
Teschke, 2015 [10]
Ernst, 2006 [41]
Wang, 2007 [42]
Tang, 1999, 2008 [43,44]
‚ Safety
Most TCM herbs are well tolerated by the majority of users, but few are
not. RCTs should evaluate the individual benefit-risk profile for each
herbal TCM product. It is important to define product quality
specifications and adherence to the principles of cGAPs and cGMPs.
Ekor, 2014 [3]
Liu, 2015 [8]
Melchart, 2016 [13]
Northier, 2000, 2002 [45,46]
Vanherweghem, 1998 [47]
Wagner, 2013 [48]
WHO, 2016 [49]
Frenzel, 2016 [50]
‚ Hepatotoxicity
Causality assessment is often missing, must be verified by RUCAM for
each spontaneous and clinical trial report submitted to regulatory
agencies and for each case report submitted to a scientific
journal for consideration of publication.
Frenzel, 2016 [50]
Danan, 2016 [51]
‚ Regulatory requirements
Less strict regulatory surveillance is risky for consumers, calling for
substantial improvement. Regulatory definitions of indications and use
are mandatory. Herbal TCM products for medicinal use should be
approved by regulatory agencies and registered as herbal drugs,
provided efficacy is validly established and their benefit-risk balance
is favorable.
Liu, 2015 [8]
Zhang, 2012 [12]
Frenzel, 2016 [50]
‚ Nomenclature
Variable nomenclature of herbal TCM products causes confusion,
requiring CMM international name standards. Unlike Latin scientific
names, CMM names, be they Chinese, pin yin, English, or according to
pharmacopoeia, have not been standardized and their use, spelling and
occasionally even the plant species to which they refer vary from
publication to publication.
Chan, 2012 [52]
cGAPs, current Good Agricultural Practices; cGMPs, current Good Manufacturing Practices; CMM, Chinese
Material Medical; RUCAM, Roussel Uclaf Causality Assessment Method.
3.4. Integration of Herbal TCM into Western Medicine
The integration of herbal TCM into modern medicine has been the subject of ongoing international
discussions in the last few years [1,2,4,5,33,49,54]. Ancient herbal TCM and modern medicine
have evolved under different empirical, theoretical, philosophical, and cultural conditions, each
attempting to establish cornerstones of valid diagnostic and therapeutic principles and to provide
efficient healthcare. However, the opinion prevailed that the situation of ancient herbal TCM is
partially disappointing [10,55], requiring substantial improvements with the tentative aim to develop
a pragmatic modern herbal TCM that meets the needs of modern medicine and possibly combines
both medicinal cultures by bridging the gap between the herbal TCM and Western medicine [10].
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3.5. New TCM Drugs and Approaches of Research and Development
Health care systems around the world are increasingly facing the problems of chronic illnesses
and their associated cost, which may be reduced by the use of herbal TCM products. Cancer treatment
is one of the most promising areas where there would be a considerable potential for the development
of new drugs derived from TCM plants [8,20,49,56–58]. Drugs such as topotecan, irinotecan and
camptothecin derivatives used for cancer therapy are good examples of drug development based on
herbal TCM [57]. In the future, several herbal TCM products [57,58] including artemisinin [57] will
have a high potential to advance drug discovery and development in a major world market, which
stands at about $83 billion, while Europe accounts for over 50% of the total [49]. Perhaps with few
exceptions [8,58], the lack of robust evidence from randomized controlled trials (RCTs) is hindering
acceptance of herbal TCM by the mainstream Western healthcare [9,10,42].
3.6. Therapeutic Efficacy
Therapeutic efficacy is a crucial criterion for the use of herbal TCM in the face of rare serious
adverse reactions such as severe liver injury or ALF [6,7]. Through randomized controlled trials (RCTs),
multiple studies attempted to validly establish efficacy of treatments by herbal TCM [9,10,42,43]. In fact,
publications of TCM trials are abundant [42,43], considering publication figures of around 10,000 [43]
or 26,263 [42], but their scientific quality is limited [9,10,42,43]. One of these studies identified 37,252
Chinese language articles in TCM journals published in mainland China, with clinical trials recognized
in 26,263 out of 37,252 articles, corresponding to 70.5% [42]. Out of these 26,263 clinical trials, 7422
were initially identified as RCTs, equivalent to 28.3%, but among these 7422 trials, only 1329 (17.9%)
were truly randomized [42].
In more detail, some important methodological components of the RCTs were missing, such
as sample size calculation (reported in 1.1% of RCTs), randomization sequence (7.8%), allocation
concealment (0.3%), implementation of the random allocation sequence (0%), and intention to treat
analysis (0%) [42]. All reports were searched according to guidelines of the Cochrane Centre, and
a comprehensive quality assessment of each RCT was completed using a modified version of the
CONSORT checklist [42]. The poor quality of many TCM RCTs [42] was continuously discussed in
various reports during the last decades, as summarized recently [10].
Regrettably, most Cochrane systematic reviews of TCM are inconclusive, due specifically to
the poor methodology and heterogeneity of the studies [9]. It is well recognized that planning and
performing RCTs, data analysis and compilation are cumbersome, time consuming, and expensive [9],
with additional efforts having to be put into editorial and reviewing work. Unless strict criteria are
applied for clinical trials of alternative medicinal systems including herbal TCM, these studies will
not be regarded as valid. For most analyses such as those evaluated in this review, major quality
criteria are violated, including primary research hypothesis formulation, clinical inclusion criteria
and outcome parameters, and appropriate statistical analysis [10]. RCTs require clearly defined drug
and usage characteristics, which cannot be provided for herbal TCM formulae that are prescribed
individually and not uniformly for each patient.
RCT reports of TCM herbs have been increasingly published since 1990, but the reason for a sharp
drop of reports within the last two years is unclear (Figure 1).
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3.7. Safety
In analogy to other herbs [59], TCM herbs may be classified as good ones, bad ones, and ugly
ones [25]. For some herbal medicines including herbal TCM products, safety concerns have been
expressed regarding rare adverse reactions that were not always transient but occasionally resulted
in a severe clinical course and fatality [2,7,12,28,29]; attempts to ignore severe adverse reactions
should be resisted [55]. Under these conditions, manufacturers and regulatory agencies are obliged
to provide good product quality of efficient herbal products including herbal TCM, ascertaining
consumer safety [12,50,60,61]. Certainly, the majority of TCM plants are harmless and well tolerated
by most consumers [3,13]. As with any conventional treatment, the use of herbal TCM products
may be associated with only mild and transient adverse effects that are without clinical relevance
(Table 2) [3,13].
Table 2. Adverse reactions of patients treated ith herbal TC .
Reported Side Effects Patients (n) Patients (%)
Liver adaptation 3 0.3
Liver injury 3 0.3
Diarrhea 46 4.6
Nausea 11 1.1
Vomiting 4 0.4
Other gastrointestinal symptoms 103 13.4
Neuro-vegetative symptoms 61 6.1
Aggravation of pain 36 3.6
Adverse reactions are presented for 994 patients treated with herbal TCM as decoction in the
TCM-hospital Bad Kötzting, 2013 (Table 2) [13]. Liver adaptation refers to values of ALT (Alanine
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aminotransferase) <5 N (upper limit of normal), while liver injury is based on ALT ě5 N [51]. In the
three cases of liver injury, RUCAM based causality was only “possible”.
Because safety aspects are an outstanding problem (Table 1) [2,28,29,60] and due to variable
and disputable product quality [13,62–65], herbal TCM products require a more strict regulatory
surveillance in China and elsewhere [8,12,50]. Some efforts appear promising [12], provided the
principles of current Good Agricultural Practices (cGAP) and current Good Manufacturing Practices
(cGMP) are fulfilled [8,12,50,60]. In essence, herbal TCM products intended for medicinal purposes
and fulfilling regulatory requirements of efficacy and safety, should all be classified as regulated herbal
drugs [50]. Such strict regulatory surveillance should be expanded to dietary supplements (DS); most
of these include herbal ingredients [61]. The abundance of DS is frightening, as for instance more than
50,000 DS were marketed in the United States between 1995 and 2015, a real regulatory challenge [61].
A more stringent regulatory approach would reduce the number of products and allow for more
transparency [50].
Eighteen years ago, inconsistent botanical nomenclature of TCM herbs with similar Chinese
names provoked shocking publicity of a case of falsification, when the root of Stephania tetrandra (Han
Fang Ji) was confused with the root of Aristolochia fangchi (Guang Fang Ji) (Figure 2) [45–47]. The mix
up herb intended for weight loss was consumed by women as tea medication that produced severe
nephrotoxic adverse effects. The TCM Aristolochia herbal product contains the carcinogenic aristolochic
acid [45]. Meanwhile, special quality proof methods like TLC (Thin-Layer Chromatography) and
HPLC-fingerprint technique (High Performance Liquid Chromatography) of Chinese drugs was able
to detect minimal concentrations of these toxic acids in single herb products or herbal drug mixtures
in order to avoid cases of poisoning [48]. In the near future, the barcode fingerprint DNA analysis
will also be available, in order to supplement the chromatographic analysis [48]. All these methods
should help to fulfill the basic requirements for quality proof of Chinese herbs including botanical
authenticity, species diversity, safety check for adulterations, processing of herbal drugs on the bench,
optimal extraction methods, and standardization of herbal extract combinations [48,66].
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3.8. Nomenclature
Nomenclature variability of individual TCM herbs and herbal TCM products such as herbal
mixtures consisting of multiple TCM herbs are considered as a specific problem [52,55], especially
when scientific reports have to be interpreted in relation to a TCM herb [52]. Unlike Latin scientific
names, CMM names, be they Chinese, pin yin, English, or according to pharmacopoeia, have not
been standardized and their use, spelling and occasionally even the plant species to which they refer
vary from publication to publication [52]. The monographs in the Chinese Pharmacopoeia also vary
in their species delimitation from one edition to the next, and Latin names should never be derived
from Chinese Materia Medica (CMM) names alone. Available as proprietary medicines or crude
herbal mixtures, herbal TCM formulae may also differ in composition depending on country or origin,
manufacturer or even individual practitioner [51]. These difficulties are amplified by the large number
of TCM plants in China [10].
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Currently, around 13,000 herbal preparations are listed in the CMM, and are available in China [67,68],
being officially recognized and described in detail by the Chinese Pharmacopoeia [67,69], including
herbs commonly used, regional variations and folk medicine variants. The CMM [69] is a reference
book that also describes thousands of plant preparations [6], including some nonbotanical elements
(animal parts and minerals) [6,53,55,67] incorrectly classified as herbal medicines [34]. Outside of
China, only around 500 Chinese herbs are commonly used [67].
4. TCM Herbs with Published Claims of Hepatotoxic Potential
4.1. Compilation of TCM Herbal Products with Reported Claims of Liver Injury
It is particularly challenging to compile all potentially hepatotoxic TCM herbs and herbals
products, but an attempt is warranted to provide at least first data on this issue. Several limitations
of this approach have to be acknowledged. Completeness of the listing is hardly achievable since
systematic compilations of TCM HILI cases are not available. There is also the problem of how to
define criteria of the cases that should be included.
In all suspected cases of HILI caused by TCM as published in scientific journals, the authors claim
causality for the reported herbal TCM product; otherwise the submitted paper would have not been
accepted for publication. Assumed causality was mostly based on clinical judgment, rarely on the
results of liver specific causality assessment methods [70–179] such as RUCAM [51,180]. Among the
published reports, a large number of assessments provide only a possible causality level, which is fair
enough but in essence of little clinical or regulatory relevance. Published reports are therefore hardly
assessable by others due to incomplete data presentation and confounding variables. These include for
instance lacking a temporal relationship between product use and the occurrence of liver injury itself
poorly defined, unclear product description and quality, insufficient exclusion of alternative causes
including viral and namely HEV infections, and no data on preexisting liver diseases. Despite these
limitations, stakeholders including regulatory agencies, physicians, and patients taking these herbal
TCM products are informed that such hepatic reactions could occur (Table 3).
Table 3. Compilation of reported herbal TCM products with suspected hepatotoxicity.
Chinese Name Botanical Names, Main Ingredients
‚ Ai Ye Artemisia argyi.
‚ An Shu Ling Lycopodium serratum or rarely, Corydalis species, Panax ginseng, Pseudo ginseng, or two species
of Stephania.
‚ Bai Fang Angelica sinensis, Cyperus rotundus, Ginseng, Ligusticumwallichii, Paeonia alba, Rehmannia glutinosa.
‚ Bai Shi Wan
Atractylis, Carthamus tinctorius, Dalbergia odorifera, Dioscorea bulbifera, Glycyrrhiza, Lithospermum
erythrorhizon, Paeonia suffruticosa, Polygonum multiflorum, Psoralea corylifolia, Salvia miltiorrhiza;
Endoconcha sepiae, Ganoderma lucidum (mushroom).
‚ Bi Ma Zi Rhicinus communis, Chaenomeles, Codonopsis pilosula, Notopterygium, Polygonum multiflorum,
Rehmannia, Schisandra.
‚ Bo He Mentha haplocalyx.
‚ Bo Ye Qing Niu Dan Tinospora crispa.
‚ Bofu Tsu Sho San
Angelica, Atractylis, Cnidium, Gardenia, Ephedra, Forsythia, Glycyrrhhiza, Gypsum fibrosum,
Ledebouriella, Mentha, Paeonia, Platycodon, Rheum, Schizonepeta, Scutellaria, Zingiber ; Kadinum
(talcum powder), sodium sulfuricum.
‚ Boh Gol Zhee Psoralea corylifolia.
‚ Cang Er Zi Xanthium sibiricum.
‚ Chang Shan Dichora febrifuga Lour.
‚ Chai Hu Bupleurum falcatum.
‚ Chaso Camellia sinensis, Cassia tora (syn. Senna), Crataegus, N-nitroso-fenfluramine.
‚ Chi R Yun Breynia officinalis.
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Table 3. Cont.
Chinese Name Botanical Names, Main Ingredients
‚ Chinese herbal
mixtures (various)
Dictamnus dasycarpus, Gentiana scabra, Hedyotis diffusa, Paeonia suffructicosa, Paris polyphylla,
Rehmannia glutinosa, Smilax glabra, Sophora subprostrata; Angelica sinensis, Bupleurum chinese,
Dictamnus dasycarpus, Paeonia suffructiosa, Philodendron chinese, Saposhnikovia divaricata, Shisandra
chinesis, Shizonepeta tenuifolia, Tribulus terrestris; Cocculus trilobus, Dictamnus dasycarpus, Eurysolen
gracilis, Glycyrrhiza, Lophatherum, Paeonia, Potentilla, Rehmannia glutinosa; Alisma plantago aquatica,
Artemisia capillaris, Gardenia jasminoidis, Gentiana scabra, Glycyrrhiza, Magnolia, Paeonia, Plantago
asiatica, Saussurea Lappa.
‚ Chuan Lian Zi Melia toosendan.
‚ Ci Wu Ji Acanthopanax senticosus.
‚ Da Chai Hu Tang Bupleurum falcatum, Ginseng, Glycyrrhiza glabra, Pinellia, Scutellaria, Zingiber officinale,Zizyphus jujuba.
‚ Da Huang Rheum palmatum.
‚ Du Huo Angelica archangelica.
‚ Fu Fang Qing Dai Wan Angelica dahurica, Isatis indigotica (Indigo naturalis), Massa medicata fermentata (yeast), Salvia
milthiorrhiza, Smilax glabra.
‚ Gan Cao Glycyrrhiza uralensis, syn. Liquorice.
‚ Ge Gen Pueraria lobata, syn. Arrowroot.
‚ He Huan Pi Albizia julibrissin.
‚ Ho Shou Wu Polygonum multiflorum, syn. He Shou Wu.
‚ Hu Bohe You Mentha pulegium, syn. Pennyroyal oil.
‚ Hu Zhang Polygonum cuspidatum.
‚ Huang Qin Scutellaria baicalensis.
‚ Huang Yao Zi Dioscorea bulbifera.
‚ Hwang Geun Cho Corydalis speciosa.
‚ Ji Gu Cao Abrus cantoniensis.
‚ Ji Ji Chloranthus serratus.
‚ Ji Xue Cao Centella asiatica, syn. Gotu Kola.
‚ Jiguja Hovenia dulcis.
‚ Jin Bu Huan Lycopodium serratum or rarely, Corydalis species, Panax ginseng, Pseudo ginseng, or two speciesof Stephania.
‚ Jue Ming Zi Cassia obtusifolia, syn. Senna.
‚ Kamishoyosan Angelica sinensis, Atractylodes racea, Bupleurum falcatum, Gardenia, Glycyrrhiza glabra, Menthahaplocalyx, Moutan, Paeonia alba, Sclerotium Poriae Cocos, Zingiber officinale.
‚ Kudzu Pueraria thunbergiana.
‚ Ku Lian Zi Melia azedarach.
‚ Lei Gong Teng Tripterygium wilfordii Hook.
‚ Lui Hui Aloe vera.
‚ Long Dan Xie
Gan Tang
Acebia, Alisma, Angelica sinensis, Bupleurum, Gardenia, Gentiana, Glycyrrhiza, Plantago,
Rehmannia, Scutellaria.
‚ Lu Cha Camellia sinensis, syn. Chinese green tea.
‚ Ma Huang Ephedra sinica.
‚ Mao Guo Tian Jie Cai Heliotropium lasiocarpum.
‚ Onshido Aloe, Camellia sinensis, Crataegus, Gynostemma pentaphyllum makino, Raphanus;N-nitroso-fenfluramine.
‚ Qian Li Guang Senecio scandens.
‚ Qibao Meiran Wan Polygonum multiflorum, Angelica sinensis, fructus psoraleae (Yan Shuizhi), wolfberry fruit, Cuscutaspecies, poria cocos, achyranthes bidentata.
‚ Ren Shen Panax ginseng.
‚ Sairei To Alisma, Atractylis, Bupleurum, Cinnamomum, Ginseng, Glycyrrhiza, Pinellia, Polyporus, Poria,Scutellaria, Zingiber, Zizyphus.
‚ Shan Chi Gynura segetum.
‚ Shang Lu Phytolacca acinosa.
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Table 3. Cont.
Chinese Name Botanical Names, Main Ingredients
‚ Shen Min
Black cohosh, Burdock, Cayenne pepper, Ginkgo biloba, Horse chestnut, Piper nigrum,
Polygonum multiflorum, uva ursi; biotin, collagen (hydrolyzed), niacin, pantothenic acid, silica
(from plant sources), soy isoflavones, vitamin A, vitamin B6.
‚ Shi Can Teucrium chamaedrys, syn. Germander.
‚ Shi Liu Pi Pericarpium granati.
‚ ShouWu Pian
Achyranthes bidentata, Cuscuta chinensis, Eclipta prostrata, Ligustrum lucidum, Lonicera japonica,
Morus alba, Polygonum multiflorum, Psoralea corylifolia, Rehmannia glutinosa, Rosa aevigat, Sesemum
indicum, Siegesbeckia orientalis.
‚ Tian Hua Fen Trichosanthes kirilowii.
‚ White flood
Qian Ceng Ta (Huperzia serrata), Wu Zhu Yu Evodia rutaecarpa); beet root, caffein, cocoa bean,
vinpocetine (from Vinca plant); acesulfame potassium, calcium silicate, carnitine tartrate,
Carno-Syn®beta-alanine, citrulline, cryptoxanthin, folic acid, gamma-aminobutyric acid
(GABA), glucuronolactone, selenium, L-norvaline, L-tyrosine, lutein, malic acid, ornithine,
potassium gluconate, sucralose, sugar cane, water melon flavor, zeaxanthin.
‚ Wu Bei Zi Galla chinensis.
‚ Xi Shu Camptotheca acuminate.
‚ Xian Si Zi Abrus Precatorius.
‚ Xiao Chai Hu Tang Bupleurum falcatum, Ginseng, Glycyrrhiza glabra, Pinellia tuber, Scutellaria baicalensis, Zingiberofficinale, Zizyphus jujuba.
‚ Yin Chen Hao Artemisia capillaris.
‚ Zexie Alisma orientalis.
‚ Zhen Chu Cao Phyllanthus urinaria.
Data are compiled from various reports, including references published previously [7,50,53,70,143,181,182].
In few cases, causality for specific TCM herbs or herbal mixtures was established by using RUCAM. For other
cases, information was scarce and did not necessarily allow for causality assessment.
4.2. Worldwide Reports
Considering the worldwide publications preferentially in the English language, there were
two reports on TCM HILI during the period from 1984 to 1993 [180]. This was followed by
20 publications from 1994 to 2003 and 55 reports from 2004 to 2013. With 28 publications for the
period from 2004 to 2008 and with 27 reports from 2009 to 2013, the publication frequency was stable in
recent years [180]. The variability of countries from which the reports originated is high [53]. Of note,
the use of herbal TCM is popular in Germany, but liver injury appears not to be a problem [13,14,183],
at least in one study, considering that RUCAM based causality in the three cases of liver injury was
only possible (Table 2) [13].
Cases of suspected TCM HILI occurred in various countries and were published with details such
as case series and case reports, mostly with highly informative narratives [70–179]. Additional data
may be derived from review articles and other publications, which partially covered also large
cohorts [181,182,184–190].
Clearly, many Chinese individuals consume herbal TCM products, and the majority of TCM
HILI cases are obviously published in scientific journals in the Chinese language, thereby not easily
assessable by Western scientists. Therefore, whatever is published in the English language in Western
journals on HILI by TCM, this may just be the tip of an iceberg. The total number of regulatory HILI
cases due to herbal TCM products is also unknown, as submitted to and archived in the regulatory
agency, the China Food and Drug Administration (CFDA) in Beijing, also known as Center for Drug
Reevaluation. Subsequently, any compilation of suspected HILI involving TCM will be necessarily
incomplete [184]. For reasons of transparency and scientific evaluation, spontaneous reports of cases of
HILI by TCM submitted to CFDA should be published with a narrative, a list of excluded alternative
causes, and a RUCAM based causality assessment [51]. This approach would facilitate considerations
on how safety of these products can be improved. The top ranking of reporting countries focused on
Medicines 2016, 3, 18 12 of 60
Hong Kong, Korea, Japan, and the United States, whereas reports originating from European countries
were unexpectedly scarce, as evidenced by evaluation of selected reports (Table 4).
Table 4. Country/Area listing of selected reports of suspected HILI caused by TCM.
Country/Area Cases (n) References with First Author
‚ Argentina 3 Jorge, 2005 [112]
‚ Australia 1 Park, 2001 [156]
‚ Canada 1 Divinsky, 2002 [116]
‚ Columbia 1 Cárdenas, 2006 [151]
‚ France
7 Larrey, 1992 [168]
26 Castot, 1992 [169]
1 Mostefa-Kara, 1992 [170]
1 Diaz, 1992 [171]
1 Ben Yahia, 1993 [172]
1 Dao, 1993 [173]
1 Mattéi, 1999 [175]
1 Peyrin-Biroulet, 2004 [133]
‚ Greece 1 Starakis, 2006 [176]
‚ China
2 Dai, 2006 [124]
1 Chen, 2007 [128]
41 Wu, 2008 [119]
1 Li, 2010 [129]
116 Gao, 2012 [122]
146 Zhou, 2013 [184]
1 Li, 2015 [165]
40 Wang, 2015 [164]
15 Zhu, 2015 [189]
563 Zhu, 2016 [188]
‚ Hong Kong
4 Kumana, 1983, 1985 [125,126]
1 But, 1996 [155]
7 Yuen, 2006 [82]
3 Cheung, 2009 [88]
52 Lin, 2011 [120]
‚ Italy
1 Picciotti, 1998 [117]
1 Mazzanti, 2004 [157]
36 Mazzanti, 2009 [138]
1 Valente, 2010 [154]
19 Mazzanti, 2015 [141]
‚ Japan
4 Itoh, 1995 [178]
1 Kamiyama, 1997 [91]
12 Adachi, 2003 [93]
1 Aiba, 2007 [166]
1 Motoyama, 2008 [83]
21 Gono, 2010 [106]
1 Furukawa, 2010 [159]
1 Tsuda, 2010 [167]
1 Inoue, 2011 [92]
‚ Korea
1 Hwang, 2001 [86]
1 Nam, 2005 [87]
4 Jang, 2008 [75]
120 Kang, 2008 [79]
24 Sohn, 2008 [80]
1 Kang, 2009 [111]
2 Kim, 2009 [104]
1 Bae, 2010 [105]
25 Jung, 2011 [153]
1 Yang, 2012 [108]
3 Kim, 2012 [113]
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Table 4. Cont.
Country/Area Cases (n) References with First Author
‚ Macedonia 1 Huseini, 2016 [142]
‚ Netherlands 1 Panis, 2005 [152]
‚ Slovakia 1 Banarova, 2012 [160]
‚ Spain
1 Garcia-Moran, 2004 [132]
1 Jimenez-Saenz, 2006 [134]
8 Garcia-Cortés, 2008 [136]
‚ Taiwan
61 Lee, 2011 [90]
2 Lin, 2002 [97]
19 Lin, 2003 [98]
1 Hsu, 2006 [179]
‚ United Kingdom
1 Davies, 1990 [100]
1 Graham-Brown, 1992 [76]
1 Sanders, 1995 [101]
3 Kane, 1995 [77]
1 Vautier, 1995 [78]
1 Skoulidis, 2005 [148]
7 Woolf, 1994 [114]
1 Nadir, 1996 [145]
‚ United States
6 Horowitz, 1996 [115]
1 Borum, 2001 [147]
2 Haller, 2002 [70]
7 Estes, 2003 [74]
1 Bonkovsky, 2006 [135]
1 Laird, 2008 [158]
34 Sarma, 2008 [137]
1 Linnebur, 2010, [107]
1 Cohen, 2012 [177]
1 Cortez, 2012 [81]
1 Yang, 2012 [108]
1 Dhanasekaran, 2013 [109]
47 Navarro, 2013 [139]
1 Papafragkakis, 2016 [110]
5. Narratives of TCM HILI Cases
Most appreciated for case analyses are detailed descriptions of product ingredients, product use,
and clinical characteristics, but many reports of TCM HILI lack such informative narratives and may
easily be disqualified due to incomplete data. Rather than publishing many cases of poor quality and
low causality levels, the preferred approach would be to publish fewer cases of suspected TCM HILI
with RUCAM based causality gradings of “probable” or “highly probable” to ensure correctness of the
TCM HILI diagnosis. Such qualified cases can then be used to characterize clinical features of patients
with liver injury by a single TCM herb or herbal mixture.
5.1. An Shu Ling
A 42-year old woman of the United States took three different herbal medicines for insomnia [70].
The products were An Shu Ling (syn. Jin Bu Huan) as TCM, “Ignatia Amara” and “Relaxed
Wanderer”. Following this treatment for 10 weeks, she experienced acute liver injury and jaundice.
Poison specialists at the California Poison Control System in San Francisco searched the Poisindex
(Micromedex, Englewood, CO, USA) and found the synonym Jin Bu Huan listed for An Shu Ling,
its chemical analysis identified L-tetrahydropalmitine, the hepatotoxic ingredient, present also in Jin
Bu Huan that also contains Stephania sinica among other herbs. The two other herbal products were
analyzed and contained no known hepatotoxins. The product lot of An Shu Ling was confiscated
from the importer-seller, and a public health warning was issued. No additional cases associated
with the use of this particular product were reported. Although Jin Bu Huan itself was banned from
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importation into the United States due to the risk of HILI, this shipment of An Shu Ling reportedly
cleared US customs because the shipping invoice mentioned only the Chinese botanical name [70].
See also Jin Bu Huan.
5.2. Ba Jiao Lian
After drinking infusions of the TCM Ba Jiao Lian (Dysosma pleianthum) taken at recommended
doses, five patients in Taiwan experienced abnormal liver tests, nausea, vomiting, diarrhoea, abdominal
pain, thrombocytopenia, leucopenia, sensory ataxia, altered consciousness and persistent peripheral
tingling or numbness [71]. In a recent report from Taiwan, 17 cases associated with poisoning by Ba
Jiao Lian were reported [72]. Podophyllotoxin is one of the main ingredients of the Ba Jiao Lian root
and considered to be the toxic agent [71–73]. However, the increase of the aminotransferases was mild,
with predominance of aspartate aminotransferase (AST) over alanine aminotransferase (ALT) [71–73].
The increase in AST [71] could also reflect either an isolated damage of liver mitochondria or muscular
damage [71,73] because of the associated increase of creatine phosphokinase [71]. These uncertainties
do not allow for the classification of Ba Jiao Lian as a hepatotoxic TCM herb, and therefore it will not
further considered within this review.
5.3. Bai Fang
A 54-year old male patient in the United States developed subtotal liver necrosis and survived
following LTX [74]. He used Bai Fang as a herbal TCM for an unknown period of time and had an
acute HBV infection as concomitant disease. Bai Fang is a herbal mixture that includes Angelica sinensis,
Cyperus rotundus, Ginseng, Ligusticum wallichii, Paeonia alba, and Rehmannia glutinosa. The possible
hepatotoxic herb and its suspected ingredient are unknown. The causal role of Bai Fang may be
questioned in this case report because of the concomitant acute HBV infection. No other cases were
reported involving Bai Fang.
5.4. Bai Xian Pi
In four Korean patients, the use of the herbal TCM Bai Xian Pi (Dictamnus dasycarpus) was
hepatotoxic, when applied as a single herb [75], and in three other patients from the United Kingdom,
when it was coadministered with other herbs [76–78]. Fourteen patients from Korea developed ALF
due to Dictamnus dasycarpus [79], and two other Korean patients experienced ALF that needed a liver
transplant [80]. See also Chinese herbal mixtures.
5.5. Ban Tu Wan
A middle-aged Asian female patient living in the United States experienced ALF secondary to
the use of the TCM Ban Tu Wan [81]. The components of this herbal mixture are Angelica sinensis,
Chaenomeles, Codonopsis pilosula, Notopterygium, Polygonum multiflorum, Rehmannia, and Schisandra.
The patient was evaluated for a liver transplantation but died from septicemia before this
procedure [81]. No other cases caused by Ban Tu Wan were published. See also Ho Shou Wu,
Polygonum multiflorum, Shen Min, and Shou Wu Pian.
5.6. Bo He
A 45-year and 46-year old men from Hong Kong with chronic HBV infection took the TCM Bo
He (Mentha haplocalyx) in herbal mixtures that contained 11 other ingredients. Bo He is known to be
hepatotoxic in the Chinese literature [82].
5.7. Bofu Tsu Sho San
A 37-year old Japanese woman used the herbal TCM Bofu Tsu Sho San, a Japanese kampo
medicine also called Bofu Tsusho San and experienced liver injury [83]. Bofu Tsu Sho San contains
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16 herbs, Angelica, Atractylis, Cnidium, Gardenia, Ephedra, Forsythia, Glycyrrhhiza, Gypsum fibrosum,
Ledebouriella, Mentha, Paeonia, Platycodon, Rheum, Schizonepeta, Scutellaria, and Zingiber, as well as
Kadinum (talcum powder) and sodium sulfuricum [84]. Several herbs are candidates for liver injury,
including Ephedra providing the hepatotoxic ephedrine [85]. For Ephedra see also Ma Huang.
5.8. Boh Gol Zhee
Acute liver injury was described after the use of the TCM Boh Gol Zhee (syn. Bol Gol Zhee,
Bu Gu Zhi, Bu Ku Zi, Sheng Bu Gu Zhi, Sheng Po Gu Zhi) in two patients in Korea [86,87] and in
three patients in Hong Kong [88]. Boh Gol Zhee is not a herbal mixture but contains only seeds of
Psoralea corylifolia with psoralens as possible hepatotoxic ingredients, especially when used in large
amounts [86–88]. Psoralens are also hepatotoxic candidates in another patient, who experienced severe
liver injury after the use of Indian Ayurvedic herbal products [89]. These included Bakuchi tablets
with extracts from Psoralea corylifolia leaves with psoralens to treat her vitiligo.
5.9. Bupleurum
See Chai Hu.
5.10. Camellia Sinensis
See Lu Cha.
5.11. Chai Hu
The risk of liver injury might be increased in Taiwan patients with chronic HBV infections treated
with TCM products containing Chai Hu (Bupleurum falcatum) [90]. In particular, two products were
involved: Xiao Chai Hu Tang and Long Dan Xie Gan Tang. In other patients without chronic HBV
infection, herbal TCM products containing Bupleurum might be hepatotoxic, see for instance Da Chai
Hu Tang [91], Kamishoyosan [92], and a report referring to a herbal TCM mixture [77].
5.12. Chaso
Six Japanese patients developed hepatic injury due to the use of the herbal weight loss
aid Chaso of TCM [93]. This product contained Camellia sinensis (Green tea, syn. Lu Cha as
TCM), the hepatotoxic Cassia tora (Senna), Crataegus, Chrysanthenum morifolium Ramat, Lotus, and
Lycium barbarum. Camellia sinensis extract is a known weight loss aid, most likely present as extract
in the Chaso formula to facilitate weight loss. It was not considered as the offending agent [93],
since the hepatotoxicity of Camellia sinensis extract was unknown in 2003 when Chaso hepatotoxicity
was described. Outcome was favorable in all patients including one patient treated with liver
transplantation. Chemical analysis of the Chase product showed lack of fenfluramine and heavy
metals such as copper, lead, bismuth, cadmium, stibium, stanum, mercury, and chromium, but
N-nitroso-fenfluramine was found. N-nitroso-fenfluramine was considered as possible but not yet
proven to be a hepatotoxin [93], similar to other cases of liver injury due to various other slimming
aids in the United Kingdom [94], Hong Kong [95], and Japan [96], including the TCM herbal product
of Onshido [93]. An additional 21 Chaso-induced cases of liver injury were reported to the regulatory
agency in Japan and not further analyzed [93]. A cautionary statement of the authors asked for further
toxicological analysis to demonstrate a possible hepatotoxicity of N-nitroso-fenfluramine, which was
not established toxicologically or clinically before 2003 [93]. Toxicological evidence of its potential
hepatotoxicity has not been brought since 2003, and clinical evidence will be difficult to report due to
the removal of this ingredient from the market in 1997. The popular and widely used slimming aid
fenfluramine was withdrawn from the market mainly due to cardiac and pulmonary adverse reactions
rather than hepatic adverse reactions, which were not reported [93]. For more details and discussions,
see Lu Cha (Camellia sinensis) and Onshido.
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5.13. Chi R Yun
Twenty-one Taiwanese patients used the TCM Chi R Yun (Breynia officinalis) and experienced
liver injury [97–99]. There was intentional and unintentional Chi R Yum overdose in two patients [97]
and acute poisonings in 19 patients, because Breynia officinalis was confused with a similar plant,
Securinega suffruticosa, which is not known as hepatotoxin [98,99].
5.14. Chinese Herbal Mixtures
Patients can use an unnamed, unclassified herbal mixture of TCM. In addition, in some of these
cases, only few herbs had been identified by their names. The lack of a single name of the herbal
mixture, which covers all herbs present as ingredients, did not allow ascribing one of these cases to an
existing named herbal product group.
Herbal hepatotoxicity was published for a heterogeneous group of herbal mixtures of
TCM [76–78,100–102], with the United Kingdom as the most frequent country [76–78,100,101].
In three cases, hepatotoxicity was described following herbal TCM use, but details concerning
the administered herbs were missing [76,100,101]. More information was provided in other
reports [76–78]. One treatment consisted of Dictamnus dasycarpus (syn. Bai Xian Pi), Gentiana scabra,
Hedyotis diffusa, Paeonia suffructicosa, Paris polyphylla, Rehmannia glutinosa, Smilax glabra, and
Sophora subprostrata [77]. Another patient used Angelica sinensis, Bupleurum chinese, Dictamnus
dasycarpus, Paeonia suffructiosa, Philodendron chinese, Saposhnikovia divaricata, Shisandra chinesis,
Shizonepeta tenuifolia, and Tribulus terrestris [77]. The third patient with a fatal outcome used a mixture
consisting of Cocculus trilobus, Dictamnus dasycarpus, Eurysolen gracilis, Glycyrrhiza, Lophatherum, Paeonia,
Potentilla, and Rehmannia glutinosa [76]. Considering these three cases in two reports [76,77], there
is some evidence that either Dictamnus dasycarpus or Paeonia species could be the toxic agent [77].
Analysis of a herbal remedy taken by another patient with ALF and unsuccessfully treated by LTX
confirmed the presence of Dictamnus dasycarpus and supports its causal role [78]. Supportive evidence
was also provided by four Korean patients with acute liver injury by Dictamnus dasycarpus used as a
single herb [75].
The herbal mixture of TCM used by a patient in Canada led to ALF and sucessful LTX in the United
States [102]. This mixture consisted of 12 herbs and included Alisma plantago aquatica, Artemisia capillaris,
Bupleurum, Chrysanthemum morifolium, Circuma, Gardenia jasminoidis, Gentiana scabra, Glycyrrhiza,
Magnolia, Paeonia, Plantago asiatica, and Saussurea lappa. The offending ingredient is unknown.
5.15. Chinese Skullcap
See Huang Qin.
5.16. Chuan Lian Zi
A 45-year old male patient with chronic hepatitis B virus (HBV) infection from Hong Kong was
treated with the TCM Chuan Lian Zi (Melia toosendan) and experienced herbal liver injury [82].
5.17. Ci Wu Jia
The two Korean patients took the herbal TCM Ci Wu Jia (Acanthopanax senticosus) and developed
acute liver injury with ALF requiring LTX [80].
5.18. Da Chai Hu Tang
In a Japanese patient, autoimmune hepatitis was triggered by the use of the TCM product Da Chai
Hu Tang (syn. Dai Saiko To, TJ-8), a mixture of aqueous extracts from seven plants, Bupleurum falcatum,
Ginseng, Glycyrrhiza glabra, Pinellia, Scutellaria, Zingiber officinale, and Zizyphus jujuba [91]. The offending
agent is unknown. Da Chai Hu Tang contains the same components as the potentially hepatotoxic
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TCM Xiao Chai Hu Tang (syn. Sho Saiko To Syo Saiko To, Syo Xiao Hu Tang, TJ-9) but in different
proportions [91,103]. See also Bupleurum and Xiao Chai Hu Tang.
5.19. Da Huang
A 45-year old man of Hong Kong with chronic HBV infection used the herbal TCM product Da
Huang (Rhubarbe, Rheum palmatum) and died from ALF and acute multiorgan failure as a consequence
of herbal hepatotoxicity [82].
5.20. Dai Saiko To
See Dai Chai Hu Tang.
5.21. Dan Zhi Xiao Yao San
See Kamishoyosan.
5.22. Dictamnus Dasycarpus
See Bai Xian Pi.
5.23. Gan Cao
A 46-year old man from Hong Kong with a chronic HBV infection took the TCM product Gan Cao
(syn. Glycyrrhiza uralensis, Liquorice, Gan Cao Zhi, Shen Nong Ben Cao Jing, Zhi Gan Cao) in formulas,
which contained eleven elements including Gan Cao as the likely toxic agent for the observed liver
injury [82]. Recovery was complete after discontinuation of Gan Cao.
5.24. Ge Gen
Two 57- and 58-year old women from Korea ingested juice of the herbal TCM product Ge Gen
(Pueraria lobata, syn. Arrowroot) and developed symptomatic liver injury [104]. Clinical symptoms
and laboratory findings rapidly improved following cessation of this herb and supportive care.
5.25. Glycyrrhiza Uralensis
See Gan Cao.
5.26. Ho Shou Wu
A 54-year old Korean woman took Polygonum multiflorum as the TCM product Ho Shou Wu (syn.
He Shou Wu, Shou Wu Wan, Fo Ti) and experienced acute liver injury [105]. Hepatotoxicity of Ho
Shou Wu was also assumed in a 33-year old woman in Hong Kong with a chronic HBV infection,
but comedication also consisted of the hepatotoxic Jue Ming Zi (Cassia obtusifolia tora, Senna) and
10 additional and not further identified herbal products [82].
5.27. Huang Qin
Nineteen Japanese patients developed liver injury after the use of the herbal TCM Huang Qin
(Scutellaria baicalensis, syn. Chinese skullcap), called Ogon in Kampo medicine of Japan and included
in a herbal mixture [106]. Liver injury was described in four patients of the United States who used
Huang Qin in a dietary supplement, which also contained black catechin (Acacia catechin), glucosamine,
chondroitin, and hyaluronic acid [107–109]. Acacia catechu was used as one of several Indian Ayurvedic
herbs in a patient with severe liver injury and is thereby a possible offending agent [89], although
the herbal extract of Chinese skullcap is the more likely cause of the reported liver injuries [107–109].
Another 54-year old woman in the United States experienced liver injury following use of a herbal TCM
mixture containing Chinese skullcap and black catechu for two to four weeks prior to admission [110].
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5.28. Hwang Geun Cho
A 37-year old Korean male patient consumed the herbal TCM product Hwang Geun Cho
(Corydalis speciosa) and experienced acute liver injury [111]. Symptoms disappeared and laboratory
values decreased gradually to near normal values following cessation of this herbal TCM and
supportive care.
5.29. Ji Gu Cao
A 38-year old man of Hong Kong with chronic HBV infection took the herbal TCM product
Ji Guo Cao (syn. Abrus cantoniensis, Ji Gu Cao Wan) and developed an acute liver injury, possibly also
caused by contaminating hepatotoxic seeds [82].
5.30. Ji Xue Cao
Three women aged 61, 52, and 49 years from Argentina ingested the herbal TCM product
Ji Xue Cao (Centella asiatica, syn. Gotu Kola) and developed liver injury due to Centella asiatica [112].
Outcome was favorable after discontinuation of the herbal TCM and ursodeoxycholic acid therapy.
5.31. Jia Wei Xiao Yao San
See Kamishoyosan.
5.32. Jiguja
A 3 and a half year old boy in Korea consumed tea prepared from the herbal TCM Jiguja
(Hovenia dulcis), resulting in the development of acute liver injury [113]. Due to a risk of ALF, the child
was transferred to another hospital for further evaluation and liver transplantation. References are
presented for two other cases in Korea with acute liver injury in adult patients after ingestion of
Hovenia dulcis [79,80,113], one of the patients required a LTX [80].
5.33. Jin Bu Huan
Hepatotoxicity associated with the herbal TCM product Jin Bu Huan, syn. An Shu Ling [70],
was reported in 11 patients in the United States [70,114–116] in one patient originating from
Canada [115], and in one patient in Italy [117]. L-tetrahydropalmitate is the active ingredient of
Jin Bu Huan and the suspected causative agent for liver injury. The herbal medication usually
contains only Lycopodium serratum and rarely several unrelated herbal species including Corydalis species,
Panax ginseng, Pseudo ginseng or two species of Stephania [70,114–118].
5.34. Jing Tian San Qi
Up until 2008, 41 cases in China with hepatic sinusoidal obstruction syndrome (HSOS), formerly
called hepatic veno-occlusive disease (HVOD), were reported and attributed to the herbal TCM product
Jing Tian San Qi (Sedum aizoon, syn. Stonecrop) [119]. However, the initially suspected causal role
of Sedum aizoon was obviously incorrect. Sedum aizoon lacks pyrrolizidine alkaloids (PAs), and when
applied to animals, HSOS did not occur [120]. This suggests that another herb containing PAs was
likely responsible for the reported cases [119]. In line with this is another case in Hong Kong with HSOS
that initially was ascribed also to Sedum aizoon, but it turned out to have been caused by the herbal
TCM Shan Chi (Gynura segetum) [120]. Sedum aizoon looks like Gynura segetum, but differentiation is
possible for botanical experts [120]. Comparative studies with both herbs provided clear supportive
evidence for Gynura segetum as the offending herb of cases of HSOS as compared to Sedum aizoon.
Studies showed that in mice Gynura segetum as the PAs containing herb but not Sedum aizoon lacking
PAs induces HSOS as confirmed by liver histology examination [120]. In an earlier experimental study,
a model of the hepatic veno-occlusive disease was established by pyrrolizidine alkaloids derived from
a herb described erroneously as Sedum aizoon [121], which again does not contain PAs [120,122,123]
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This suggests that the described experimental model [121] was due to the action of a herb containing
PAs, most likely Gynura segetum [120,122,123], rather than to Sedum aizoon. Based on these well founded
conclusions, evidence for a hepatotoxic potential of Jing Tian San Qi is lacking. This herbal TCM
Sedum aizoon should therefore not further be considered as hepatotoxic herbal TCM.
5.35. Ju San Qi
In two Chinese women, HSOS was induced by pyrrolizidine alkaloids of the herbal TCM
Gynura segetum (syn. Ju Shan Qi, Ju Ye San Qi, Shan Chi, San Qi Cao, Shan Chi, Shan Chi) [124].
Additional six cases were earlier suspected [125,126], in at least four cases the culprit was the PAs
containing herb Heliotropium lasiocarpum rather than Gynura segetum [127]. Two cases of HSOS were
reported in China [128,129] and another one in Hong Kong [120].
5.36. Jue Ming Zi
In a 33-year old woman of Hong Kong with a chronic HBV infection was treated with the herbal
TCM product Jue Ming Zi (syn. Cassia obtusifolia, Senna obtusifolia, Cao Jue Ming) and experienced liver
injury [82].
5.37. Kamishoyosan
In one single Japanese woman, liver injury was reported following the use of Kamishoyosan, a
traditional Japanese herbal drug (Kampo medicine) and synonym to the TCM product Jia Wei Xiao
Yao San, Dan Zhi Xiao Yao San or TJ-24 [92]. Kamishoyosan is a herbal mixture and contains several
components like Angelica sinensis, Atractylodes racea, Bupleurum falcatum, Gardenia, Glycyrrhiza glabra,
Mentha haplocalyx, Moutan, Paeonia alba, Sclerotium Poriae Cocos and Zingiber officinale, as described in
the case report [92], or assessed by an additional internet search for a refined botanical description
of the herbal components. The identification of the causative agents was difficult, but Scutellaria was
definitively excluded as it was not an ingredient of this herbal product [105,130]. Some uncertainty
exists around the Mentha species, declared as Mentha herb in the case report [92] and as mentha
(pennyroyal) subsequently [130]. Based on an internet search to further specify the Mentha species
commonly used in Kamishoyosan, Mentha haplocalyx Briq or Mentha arvensis var. piperascens Malinvaud
(Japanese field mint) was most probably the main component.
5.38. Kudzu
Six patients in Korea consumed the herbal TCM product Kudzu (Pueraria thunbergiana) and
developed acute liver injury [79].
5.39. Liquorice
See Gan Cao.
5.40. Long Dan Xie Gan Tang
A total of 14 Taiwan patients with acute and subacute HBV infection were allegedly reported
at high risk of hepatotoxicity when treated with the TCM Long Dan Xie Gan Tang (syn. Long Dan
Xie Gan Wan) [90]. This herbal mixture contains Acebia, Alisma, Angelica sinensis, Bupleurum, Gardenia,
Gentiana, Glycyrrhiza, Plantago, Rehmannia and Scutellaria. A similar increased risk of hepatotoxicity
was observed in a group of patients treated with the TCM Xiao Chai Hu Tang, which also contains
Bupleurum among other herbs. See also Bupleurum and Xiao Chai Hu Tang.
5.41. Long Dan Xie Gan Wan
See Long Dan Xie Gan Tang.
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5.42. Lu Cha
Lu Cha (Camellia sinensis, green tea) is a plant of the TCM and one of several herbal
ingredients of the two herbal mixtures Chaso and Onshido, which were marketed as weight
loss aids by Chinese pharmaceutical companies and considered hepatotoxic as described in
2003 [93]. N-nitroso-fenfluramine but not green tea was discussed as the possible but unproven
hepatotoxic ingredient for these herbal mixtures, explaining that this case series cannot prove that
N-nitroso-fenfluramine is the toxic agent [93]. Whether Camellia sinesis might have contributed to
the observed liver injury is unclear, however. Information on the amounts of green tea in these two
products was not provided. At least as extract, Camellia sinensis is a potent weight loss aid with
potentially hepatotoxic effects, as thoroughly discussed first in 2004 [131–133] and in subsequent years
as shown for many cases [134–144]. Therefore, hepatotoxicity of green tea as extracts was not yet
clearly established in 2003 when the case reports were published [93].
Green tea is one of the most popular beverages, as are black tea and coffee. There is no question
that the conventional use of these beverages including green tea does not harm the liver. In the past,
however, weight loss aids were supplemented by green tea concentrated as extracts and carried the
risk of liver injury [60,134–144,180]. According to the manufacturers, the weight loss aids Chaso and
Onshido contained green tea and other herbs [93]. Presumably, green tea was included as extracts in
these two products to enhance weight loss, although the extract form was not specifically mentioned
by the manufacturers. The producers failed to mention the synthetic adulterant N-nitroso-fenfluramine
as an ingredient of the two products to promote weight loss. This adulterant was assessed later on by
respective chemical analyses, but evidence for its hepatotoxic property was not presented and asked
for by future studies [93]. The most likely candidate for the liver injury is green tea, if supplied as the
hepatotoxic extract. For details, see also Chaso and Onshido.
Liver injury due to green tea extracts (GTE) has been reported as single cases [131–135,142],
case series [136–139,141,144], and discussed in review articles [60,139–141,180]. Overall, more than
100 suspected cases of liver injury by GTE have been published [60,180], while details of other cases
are provided by the NIH liver Tox [47].
5.43. Ma Huang
Six patients in the United States experienced acute liver injury associated with the use of the
herbal TCM product Ma Huang and its ingredients Ephedra [74,85,145–148]. Out of these six cases, one
patient received a coadministration of kava and another one of disulfiram, whereas a third one had
chronic HBV infection [74]. Two patients developed ALF [74,146], and one of these required a liver
transplant [74]. Another patient with ALF requiring a LTX was reported in the United Kingdom [149].
Ma Huang is also one of the ingredients of Pro-Lean®, a potentially hepatotoxic herbal mixture [150].
For Ephedra, see also Bofu Tsu Sho San.
5.44. Mao Guo Tian Jie Cai
Four patients from Hong Kong developed HSOS following the use of the herbal TCM product
Mao Guo Tian Jie Cai (Heliotropium lasiocarpum) [127] that contained PAs, initially mistaken as PAs
containing herbal TCM Gynura segetum [124–126]. Outcome was fatal for one patient [125].
5.45. Onshido
Six Japanese patients presented with hepatic injury due to the use of the weight loss aid
Onshido, a TCM herbal mixture [93]. This herbal product contained Aloe, Camellia sinensis, Crataegus,
Gynostemma pentaphyllum makino and Raphanus. Outcome was favorable in all patients except for
one patient with a fatal clinical course. Chemical product analysis of Onshido showed lack of
fenfluramine and heavy metals such as copper, lead, bismuth, cadmium, stibium, stanum, mercury,
and chromium, but presence of N-nitroso-fenfluramine as a possible but overall unproven hepatotoxic
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agent. N-nitroso-fenfluramine was also considered as a possible culprit in additional cases of liver
injuries due to various other slimming aids in the United Kingdom [94], Hong Kong [95], and Japan
concerning the TCM product Chaso [93]. An additional 135 Onshido-induced cases of hepatotoxicity
were reported to the regulatory agency in Japan but not further analyzed [93]. A possible role of
Camellia sinensis for the observed hepatotoxicity of Onshido was not discussed in 2003 [93], because
hepatotoxic properties of Camellia sinensis extracts became only known in 2004 [132–134]. For additional
details and discussions, see also Chaso and Lu Cha (Camellia sinensis).
5.46. Phyllanthus Urinaria
See Zhen Chu Cao.
5.47. Polygonum Multiflorum
Polygonum multiflorum is a member of the family Polygonaceae, genus Fallopia. Either alone or
combined with other herbs and vitamins, it is a component of various potentially hepatotoxic herbal
TCM products [80–82,105,150–154]. Among these are Ban Tu Wan [81], Ho Wu Shou [82,105], Shen
Min [151] and Shou Wu Pian [152–159]. Occasionally, Polygonum multiflorum containing herbal TCM
products such as Ho Shou Wu, Shen Min, Shou Wu Pian and Zhi Shou Wu are declared interchangeable
regarding their terms [150]. However, ingredients may vary from product to product, requiring specific
and qualifying product names. The mechanism of hepatotoxicity of Polygonum multiflorum is still
disputed [150–152,155–157]; the injury was sometimes attributed to the anthraquinones (such as
chrysophanol, emodin and rhein) which are the major ingredients of Polygonum multiflorum [150]. In a
single report, however, the major compound identified in the recovered tablets was a stilbene glycoside,
tetrahydroxystilbene-glucopyranoside [150,152]. LTX was necessary in three patients in Korea after
using Polygonum multiflorum [80]. A 33-year old woman from Slovakia experienced acute liver injury
after use of Polygonum multiflorum for two months [160]. Several review articles and analyzing reports
of case series of suspected liver injury by Polygonum multiflorum were published [161–164]. For instance,
a CFDA report analyzed retrospectively 24 literature cases of HILI by Polygonum multiflorum and
published its results in the Chinese language without proving causality by a liver specific causality
assessment method [161] such as RUCAM [51]. Instead, another Chinese study described valid clinical
characteristics of HILI by Polygonum multiflorum in 18 cases with “highly probable” or “probable”
causal role of this TCM herb using RUCAM criteria, all alternative infections including hepatitis E
virus (HEV) were excluded; this is really a breakthrough study that is highly appreciated and should
be used as an example for future studies on suspected HILI by TCM [162]. Similarly, other studies on
liver injury cases confirmed causality for Polygonum multiflorum, based on high RUCAM gradings and
results derived from positive reexposure tests [60,180], using published test criteria [51]. In another
systematic review of case reports and case series, 450 cases of liver injury due to Polygonum multiflorum
were analyzed regarding symptoms, outcome, and risk factors, and other criteria; however, reported
results were not convincing as causality was not ascertained by any liver specific method [163] such as
RUCAM [51]. Finally, causality in 187 cases of suspected liver injury by Polygonum multiflorum was
confirmed following assessment using RUCAM [164]. For details see also Ban Tu Wan, Chinese herbal
mixtures, Ho Wu Shou, Shen Min and Shou Wu Pian.
5.48. Qibao Meiran Wan
A 26-year-old Chinese man experienced weakness, fatigue, poor appetite, dark urine, and
jaundice after using for one month the TCM product Qibao Meiran Wan A for greying of hair [165].
The product label listed components that included Polygonum multiflorum, Angelica sinensis, fructus
psoraleae (Yan Shuizhi), wolfberry fruit, dodder, poria cocos, and achyranthes bidentata.
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5.49. Rhen Shen
Six patients originating from Korea used the herbal TCM Rhen Shen (Panax ginseng, Ren Seng)
and developed acute liver injury [79].
5.50. Sairei To
Two Japanese men consumed the Kampo medicine Sarie To (syn. Chai Ling Tang), which is
included in a blend of two TCM products, Xiao Chai Hu Tang and Wu Ling San Wan, and experienced
liver injury [166,167]. Among the Sairei To ingredients are Alisma, Atractylis, Bupleurum, Cinnamomum,
Ginseng, Glycyrrhiza, Pinellia, Polyporus, Poria, Scutellaria, Zingiber and Zizyphus. Several possible
offending agents are considered, including Pinellia ternate [166] and other components of Sairei To [167].
5.51. Shan Chi
In two 51-year and 39-year-old Chinese women, HSOS was reported as induced by PAs of the
herbal TCM Shan Chi Gynura segetum (syn. Ju San Qi, Ju Shan Qi, Ju Ye San Qi, Shan Chi, San Qi Cao,
Shan Chi), Tu San Qi) [124]. One of these patients required a liver transplant. In a 54-year-old woman
originating from Hong Kong, HSOS was finally attributed to PAs derived from Gynura segetum rather
than to the herbal TCM Jing Tian San Qi (Sedum aizoon) devoid of PAs [120]. An additional four patients
experienced HSOS after Gynura segetum consumption, one with fatal outcome [122]. In total, at least 51
HSOS cases have been reported until 2011 [120], and 116 cases until 2012 [122].
The clinical features have been clearly described, establishing Gynura segetum but not
Jing Tian San Qi (Sedum aizoon) as the cause for HSOS [120,122,123]. The diagnosis was ascertained
in the 54-year-old female patient with HSOS by thorough investigations of the patient and in
animal studies [120]. The clinical diagnosis of HSOS was firmly established by meeting the
modified Seattle criteria, characterized by hyperbilirubinaemia, hepatomegaly, and weight gain due
to fluid accumulation. Liver histology indicated that the diagnosis was HSOS, and pyrrole-protein
adducts as well as pyrrole-GSH conjugates were found in the blood and established the diagnosis.
Since the ingested herb was unknown, the cultivated herb from the patient’s home was collected and
authenticated as the TCM herb Gynura segetum. Together with the authenticated TCM herb Sedum aizoon
cultivated and collected from another Chinese area, various comparative studies in animals have
been done. All these studies confirmed that the observed HSOS arose from the consumption of the
PA-containing Gynura segetum, an erroneous substitute of the Sedum aizoon, which does not contain
PAs and has a similar name [120].
5.52. Shen Min
A 28-year-old woman originating from the United States developed in Columbia acute liver
injury following the use of the herbal TCM product Shen Min [151]. The product label for this Shen
Min product listed components including plants and vitamins. Polygonum multiflorum is one of
the main components of Shen Min, the content is described as Shen Min 12:1 standardized extract
(Polygonum multiflorum) 450 mg per serving and as He Shou Wu powder 870 mg per serving, although
Polygonum multiflorum was not specified. Other declared components of the used Shen Min product
were Vitamin A, Vitamin B6, biotin, niacin, pantothenic acid, soy isoflavones, black cohosh, horse
chestnut, hydrolyzed collagen, silica from plant sources, ginkgo biloba, uva ursi, Burdock, Cayenne
pepper and Piper nigrum. See also Ho Shou Wu, Polygonum multiflorum and Shou Wu Pian.
5.53. Shi Can
Seven patients in France experienced acute liver injury due to use of Shi Can, in Western countries
better known as germander (Teucrium chamaedrys, Teucrium polium), for three to 18 weeks [168].
After cessation of the herb, recovery was complete in all patients. In three of these, unintentional
reexposure led to prompt recurrence of the liver injury. Germander was proposed for weight control in
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the late 1980s in France, leading to a spectacular outbreak of acute liver injury within a year. This initial
report [168] triggered a national inquiry in France leading to the collection of 26 well-documented cases
of acute liver injury due to Germander [169]. Liver injury was mainly mild to moderate, occurring
about two months after starting the treatment [168,169].
Subsequently, additional cases of liver injury due to germander were reported including
two French patients with a fulminant clinical course [170,171], one with a lethal outcome [170]. In a
few patients, liver damage occurred more insidiously and was detected at the stage of chronic hepatitis
and even cirrhosis [172,173], due to long use of six to seven months [171] or large daily amounts of
several liters of herbal tea for two months [172]. In 12 patients accidentally reexposed to germander,
liver injury relapsed within a delay shorter than for the first episode of hepatitis [169]. None of the
cases had been submitted at that time to causality assessment using RUCAM or criteria of positive
reexposure tests, as both were not available when the reports were published [168–173]. There are
additional case reports that provide informative narratives [174]. For Teucrium polium, another herbal
medicine closely related to Teucrium chamaedrys, rare cases of acute liver injury have been reported
including acute liver failure (ALF) requiring liver transplantation (LTX) [175,176]. As a consequence,
Germander has been withdrawn from the market of herbal medicine in France. However, since this
outbreak, it is still used in some other countries and new cases have been observed in Canada, Belgium
and Spain [174].
5.54. Shou Wu Pian
As described already in 1996, a 31-year-old pregnant Chinese woman from Hong Kong
developed acute liver injury after consumption of the TCM product Shou Wu Pian, with Polygonum
multiflorum as the main component [155]. Subsequently, similar cases related to Shou Wu Pian
were reported in Australia [156], Canada [116], Italy [154,157], and the Netherlands in a 5-year-old
girl [152], the United States [158], Japan [159], and Korea [153]. Shou Wu Pian is a herbal mixture
with a wide variety of ingredients, but details are rarely mentioned [150,153,159]. For example,
according to the information via the internet, one of the numerous possible compositions could be:
Achyranthes bidentata, Cuscuta chinensis, Eclipta prostrata, Ligustrum lucidum, Lonicera japonica, Morus alba,
Polygonum multiflorum, Psoralea corylifolia, Rehmannia glutinosa, Rosa laevigata, Sesemum indicum, and
Siegesbeckia orientalis. This composition varies substantially from the one of Shen Min [151], which also
contains Polygonum multiflorum and is discussed above. See also Ho Shou Wu, Polygonum multiflorum
and Shen Min.
5.55. Syo Saiko To
See Xiao Chai Hu Tang.
5.56. TJ-8
See Da Chai Hu Tang.
5.57. TJ-9
See Xiao Chai Hu Tang.
5.58. TJ-24
See Kamishoyosan.
5.59. White Flood
A 23-year-old man from the United States experienced acute liver injury following use of
the commercial product White flood, which contains among others the herbal TCM Wu Zhu Yu
(Evodia rutaecarpa, club moss) and the herbal TCM Qian Ceng Ta (Huperzia serrata) [177].
Medicines 2016, 3, 18 24 of 60
Other ingredients included acesulfame potassium, beet root, caffein, calcium silicate, carnitine tartrate,
Carno-Syn® beta-alanine, citrulline, cocoa bean, cryptoxanthin, folic acid, gamma-aminobutyric acid
(GABA), glucuronolactone, selenium, L-norvaline, L-tyrosine, lutein, malic acid, ornithine, potassium
gluconate, sucralose, sugar cane, vinpocetine (from Vinca plant), water melon flavor, and zeaxanthin.
After discontinuation of the product use, the outcome was favorable.
5.60. Xiao Chai Hu Tang
The treatment with the herbal TCM Xiao Chai Hu Tang (syn. Sho Saiko To, Syo Saiko To,
Syo Xiao Hu Tang, TJ-9) resulted in liver injury in four Japanese patients with LT abnormalities before
treatment [178]. For 19 Taiwan patients with HBV infection, treatment with Xiao Chai Hu Tang was
associated with an increased risk of liver injury [90], as was for one additional patient of Taiwan
following cholecystectomy [179]. Xiao Chai Hu Tang is a mixture of several herbs, Bupleurum falcatum,
Ginseng, Glycyrrhiza glabra, Pinellia tuber, Scutellaria baicalensis, Zingiber officinale and Zizyphus jujuba.
It therefore contains the same components as the TCM Da Chai Hu Tang (syn. Dai Saiko To, TJ-8), but
in different proportions [91,103]. See also Bupleurum, Da Chai Hu Tang and Long Dan Xie Gan Tang.
5.61. Yin Chen Hao
In seven patients from Korea, the use of the herbal TCM Yin Chen Hao (Artemisia capillaris)
resulted in the development of acute liver injury [79], and one additional Korean patient required a
LTX [80].
5.62. Zexie
A 59-year old man from Hong Kong with cirrhosis and HBeAg-positive chronic HBV infection
was treated for cramps with a herbal TCM formula of 11 different herbal elements including the
hepatotoxic Zexie (Alisma orientalis) [82]. He died from complications of severe course of herbal
liver injury.
5.63. Zhen Chu Cao
A 37-year-old man from Hong Kong with a chronic HBV infection experienced acute liver injury
due to the TCM product Zhen Chu Cao experienced herbal hepatotoxicity due to Zhen Chu Cao (syn.
Phyllanthus urinaria) [82]. After cessation of this herbal product, there was a complete recovery.
5.64. Zhi Gan Cao
See Gan Cao.
6. Pathogenetic Aspects of Liver Injury from Herbal TCM
The pathogenetic events whereby TCM herbs cause liver injury are mostly unknown, as herbal
liver injury is primarily a human and not an animal disease; experimental models to study in detail the
mechanisms leading to injury are therefore rarely available. Due to their complexity and as expected,
valid considerations on pathogenetic sequelae of liver injury due to herbal TCM were provided only
for selected herbs, both in reports with a focus on narratives of case reports or small case series [70–179]
or in articles covering or reviewing larger case series [181,182,184–190].
Most processes will occur at the molecular level, considering the molecules of the phytochemicals
and the molecules of enzymes responsible for metabolic alterations of these phytochemicals in the liver.
6.1. Abundance of Herbs Used as TCM
Herbs grow at various extents in most countries of the world and provide the basis of local
traditional herbal medicine in their respective cultures [191], including China [12,69], a country rich in
plants [6,12,28,41,55,57,67–69], where around 13,000 herbal preparations are used as TCM [67–69].
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6.2. TCM Herbs and Their Molecules
In analogy with the other herbs, TCM herbs contain multiple molecules, which require elimination
in order to circumvent hazardous accumulation [25,59,140]. Therefore, these phytochemicals
must undergo enzymatic degradation and disposition following intestinal resorption by processes
similar to those known for synthetic drugs, involving bioactivation pathways via the cytochrome
P450 (CYP) systems (Phase I), conjugation to other molecules (Phase II), and excretion and transport
(Phase III) [140,192–198]. Examples for such metabolic steps are provided for many TCM herbs [194,195]
such as Polygonum multiflorum [196], Lu Cha (green tea) [140], Shi Can (germander) [199–201],
and PAs containing herbs [28,120,122,201]. Genetic variation may cause polymorphisms of
CYP [192,193], which has recently been reported also in Chinese patients with acute liver injury by
Polygonum multiflorum [196], who showed a 46.5% higher frequency of CYP1A2*1C allele as compared
to 27.9% in the healthy control group. Thus, patients with this mutation may have less CYP1A2 protein,
thereby inhibiting degradation of Polygonum multiflorum ingredients and causing accumulation of toxic
substances [196].
Other molecular risk factors of liver injury relate to the extraction process used in herbal TCM
manufacturing, which is conventionally based on decoction and alcohol sedimentation techniques [194].
Besides the water soluble components, many liposoluble constituents are included in the final herbal
TCM preparations and require biotransformation. Lipophilicity of synthetic drugs is under discussion
as a risk factor of DILI [192,198,202,203] and may have to be evaluated for liver injury by TCM herbs
as well. Results of other DILI studies related to extensive metabolism and high daily doses as risk
factors of DILI [192,204–206] could also be of relevance for TCM herbs. For instance, drugs intensively
metabolized by the liver have a higher likelihood causing DILI [192,205,206], and drugs metabolized
by CYP enzymes were four times as likely to cause DILI [192,203]. In more detail, drugs metabolized by
CYP1A2, CYP2C8/CYP2C9, and CYP3A5 were closely associated with an increased risk of DILI [203].
Drugs given in a high daily dose of >100 mg were nearly five times as likely to cause DILI a lower daily
doses [192,203]. CYPs usually detoxify various chemicals from TCM herbs but some are activated to
toxic compounds which may initiate liver injury [59].
6.3. Idiosyncratic and Intrinsic Liver Injury from Herbal TCM
Liver injury caused from herbal TCM is rare and in most cases unpredictable; defined as the
idiosyncratic type of HILI. Instead, few TCM herbs cause predictable liver injury; defined as the
intrinsic type of HILI [50,60]. Manufacturing and selling of TCM herbs with the potential for intrinsic
liver injury is unethical. In countries with strict regulatory surveillance, herbal TCM products that cause
such type of liver injury should be withdrawn from the market. Several criteria allow differentiation
of the idiosyncratic from the intrinsic liver injury by TCM [50,60].
6.3.1. Idiosyncratic Type of Liver Injury
Idiosyncratic liver injuries due to TCM herbs are not preventable as they manifest in a few
susceptible individuals with a likely genetic basis, which is commonly not known prior to the use
of TCM herbs [50,60]. Idiosyncrasy explains also many liver injury cases such as by synthetic
drugs [51,192,197,198,207] and non TCM herbs [50,60,208,209], including kava [210–213],
Chelidonium majus [214–216], and Indian Ayurvedic herbs [89]. There is little if any information of the
various steps which finally lead to idiosyncratic liver injury in the human liver cell. Case classification
of idiosyncratic liver injury due to herbal TCM requires the fulfillment of several criteria [50,51,61].
In addition to unpredictability, dose independency is another major criterion for idiosyncratic liver
injury that is further differentiated by its two subtypes, a metabolic type and an immunologic type, all
with specific criteria (Figure 3).
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Most problems of evolving liver injury will occur more likely during the metabolic degradation
of the phytochemicals due to the genetic variability of the affected individuals rather than during the
excretion of the chemical compounds. It is unknown to what extent interactions among the multiple
herbal chemicals derived from herbal TCM mixtures are causative for the liver injury. In most TCM
herbs, the chemicals which initiate liver injury are not identified. In accordance with other idiosyncratic
liver injury cases, idiosyncratic HILI due to TCM in humans develops at recommended doses and is not
reproducible in experimental animals, which do not exhibit the genetic variability or the environment of
patients who experience idiosyncratic liver injury. Consequently, the pathophysiology of idiosyncratic
liver injury from herbal TCM in humans remains undisclosed.
6.3.2. Intrinsic Type of Liver Injury
Intrinsic liver injury due to herbal TCM is predictable and hence preventable, shows a clear dose
dependency with increased risks at high doses, and is characterized by a high incidence in individuals
who consume these risky herbs (Figure 3) [50,60]. Intrinsic liver injury is also known for synthetic
drugs if used in overdose such as acetaminophen [192]. Cases of intrinsic liver injury caused by TCM
herbs are well studied due to reproducibility in laboratory animals (Figure 3).
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Among the first TCM herbs causing intrinsic liver injury was the TCM Shi Can, which consists
of Teucrium chamaedrys or other Teucrium species and is better known in Western countries as
Germander [201]. Germander hepatotoxicity fulfills all criteria of intrinsic liver injury (Figure 3),
is dose dependent, well described, and reproducible in mice [199,201]. Due to its experimental
reproducibility in laboratory animals, the molecular pathogenesis of experimental Germander
(Teucrium chamaedrys) hepatotoxicity was studied, and these results are well transferrable to human
Germander hepatotoxicity [199,201]. Neoclerodane diterpenoids are ingredients of Germander and
converted via microsomal CYP3A to reactive metabolites [199]. These deplete hepatic stores of
glutathione and cytoskeleton associated protein thiols, form plasma membrane blebs, and cause
apoptosis of liver cells [129,201], contributing to liver cell death [201]. Finally, reactive metabolites can
trigger liver injury through an immunoallergic reaction.
There is a wide range of other TCM herbs that may cause intrinsic liver injury. Among these
are herbal TCM products such as Cai Hu, Da Chai Hu Tang, Kamishoyosan, Long Dan Xie Gan
Tang, Sairei To, or Xiao Chai Hu Tang that all contain Bupleurum falcatum, mostly prepared from its
radix [90,217]; using more than 19 g as cumulative dose of Radix bupleuri may increase the risk of liver
injury [90]. This dose dependency was confirmed in laboratory animals and provided insights into
some pathogenetic processes [217].
Polygonum multiflorum is another example of a typical TCM with potential liver injury [218,219],
as shown in many case reports and case series, where this herb was used either alone or as one
among other ingredients in herbal mixtures (Table 4) [80–82,105,150–164]. These include Bai Shi
Wan, Bi Ma Zi, He Shou Wu, Ho Shou Wu, Qibao Meiran Wan, or Shen Min. Human liver
injury by Polygonum multiflorum is reproducible in laboratory animals and suggests an intrinsic
type of injury [163]. After analysis of the relevant publications, the impression prevails that
most cases of human Polygonum multiflorum hepatotoxicity seem to represent the intrinsic liver
injury [80–82,105,150–164]. However, one study favored an idiosyncratic type of injury in patients
who used the herb alone and not as part of a herbal mixture, but patients who took a herbal
mixture containing Polygonum multiflorum were exluded and not evaluated [162]. Assessing the
type of liver injury (Figure 3) is impeded by confounding variables [163]. Among these are incorrect
reporting [163], comedication [162], preexisting infections by viral hepatitis [162], water or acetone
based products [162,163,219], and the use of raw or processed Polygonum multiflorum, whereby
processing is achieved by boiling of the reddish roots with black beans [162,163,218]. Consensus exists
that both raw and processed Polygonum multiflorum can cause liver injury in humans [165,166]. For raw
Polygonum multiflorum applied to mice, the liver injury of water decocta was considerably more
pronounced than that of the acetone extract; meanwhile, the hepatotoxicity of the acetone extract
of raw Polygonum multiflorum was much higher as compared to the acetone extract of the processed
Polygonum multiflorum [218].
Therefore, processing reduced experimental liver injury. Accordingly, the CMM recommended a
daily dose of 3–6 g for the raw Polygonum multiflorum and 6–12 g for the processed product [163,219].
With a median time of 30 days, liver injury occurs when the maximum daily dose exceeds 12 g, with an
increased cumulative dose as an additional risk factor [163].
The herbal TCM Lu Cha (Chinese green tea) as extract may cause intrinsic liver injury as it occurs
dose dependently with high amounts of catechins provided by the extracts, as shown in various
reports [132–144], but human liver injury was not corroborated in a recent study [220]. Results of
experimental hepatotoxicity in animals were equivocal [221–223]. Chinese green tea is a popular
beverage prepared from the leaves of the plant Camellia sinensis, which has been cultivated in China
and other Southeast Asian countries since thousands of years [224]. Contradictory results of liver injury
obtained in humans and laboratory animals may be explained by the variability of oral bioavailability
of GT catechins. Consumed with a meal, systemic catechin levels in humans are much lower than the
effective concentrations determined in in vitro systems; they are enhanced substantially by >3.5-fold
when green tea is consumed after an overnight fast [225]. Therefore, the fasting/fed status is an
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additional confounding variable to be considered in bioavailability and liver injury evaluation studies
of catechins.
Despite few side effects, the consumption of green tea has been considered relatively safe for
most individuals when used in normal amounts [140,144,226]. On a quantitative basis, single doses
of up to 1.6 grams of green tea extract are well tolerated [140,144]. The maximum tolerated dose in
humans is reported to be 9.9 grams per day, a dose equivalent to 24 cups of green tea. The safety and
tolerability of long term use of green tea extracts has not been well defined [144]. Considering the
results of the hepatotoxicity cases [144,227,228], use of green tea or its extracts commonly ranged from
four to 260 weeks [139]. However, data of cumulative doses of catechins are not available which would
allow calculating respective threshold values.
TCM herbs containing unsaturated PAs cause intrinsic liver injury [201,229,230], as evidenced
by dose dependency [28,119–128] and reproducibility in animals [121]. Among these herbs are
Crotalaria species (Bush tea, Rattlebox), Gynura segetum, Ilex paraguarensis (Mate tea), Symphytum species
(Comfrey), Senecio species (Groundsel), Heliotropium species, and Compositae species (Indian herbs)
(Table 4), causing HSOS as a specific form of liver damage, injuring preferentially the hepatic sinusoidal
cells rather than the liver cells. The pathogenesis of liver injury by TCM herbs containing PAs has been
studied in detail [25,28,120,122,201,229,230], suggesting the involvement of hepatic microsomal CYP3A
and 2B in C-oxidation and N-oxidation of the necine base to form the reactive pyrrolic ester metabolites
and pyrrolizidine alkaloid N-oxides, respectively [25]. These metabolites damage preferentially the
sinusoidal endothelial cells of the liver and reduce thereby the sinusoidal blood flow [28]. This explains
the typical clinical features of HSOS, caused for instance by Gynura segetum [122]. However, a
conceptional gap is evident due to the incompatibility of the locations between the cells where toxic PA
metabolites are generated, namely in the liver parenchymal cell, and the offending target cell, namely
the sinusoidal endothelial cells, which became injured. Indeed, little clinical or experimental evidence
exists that hepatocytes are more affected than sinusoidal endothelial cells. HSOS due to unsaturated
PAs is clearly dose dependent, thereby predictable, and hence preventable. Consequently, every
consumer of these herbs containing PAs is at a dose dependent risk of HSOS. Plants containing PAs are
among the most abundant poisonous plants affecting not only humans but also livestock and wildlife,
with more than 6000 plant species containing PAs and about 3% of the world’s flowering plants
containing PAs [229]. Human embryotoxicity by PAs resulting in fetal HSOS has been described in a
newborn whose mother drank one cup of a tea containing PAs per day throughout pregnancy [229,231].
In the past, the CMM listed for human use many TCM herbs with toxic PAs [230]. All herbal TCM
preparations, other herbal products as well as herbal drugs destined for human use and to ensure
consumer safety must fulfill regulatory limits of PA content, which may be different from one country
to the other [232]. Efficient herbal drugs can be freed from PAs through CO2 extraction [233–235].
6.3.3. Tentative Toxic Components or Intermediates
Many reports suggested chemical ingredients as causes for various cases of liver injury due to
TCM, but these suggestions often remain speculative for human idiosyncratic liver injury due to herbal
TCM. For some TCM herbs known to cause liver injury, toxic substances have been proposed and are
listed as examples (Table 5).
Few TCM herbs merit further consideration. Among these is Shi Can (germander) with its complex
chemical composition [199,200]. It mainly contains neoclerodane diterpenoids, with a chemical
structure similar to that of other furan compounds known to be hepatotoxic. Germander components
have been shown to be mainly oxidized by CYP3A into reactive metabolites able to deplete glutathione
and cytoskeleton-associated protein thiols and cause plasma membrane blebs. Another example is
the liver injury caused by Polygonum multiflorum that is not dependent on the content of anthranoid
derivatives as previously suggested but may be correlated with the content of tetrahydroxystilbene
glucosides [218], in support of other studies [150,152]. Finally, Lu Cha (green tea) extracts cause liver
injury, but it remains unclear which of their polyphenolic catechins is the causative agent [141].
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Candidates are epigallocatechin-3-gallate (EGCG), epicatechin-3-gallate (ECG), epicatechin (EC),
epigallocatechin (EGC), and epigallocatechin-3-catechins (EGCG) [140,141]. Of these catechins,
particularly EGCG was found to be cytotoxic in isolated hepatocytes by mitochondrial membrane
potential collapse and reactive oxygen species’ formation [141,222]. EGCG is also the most abundant
catechin in the green tea extracts [140,141]. The earliest Chinese medical classic “The Inner Canon
of Huangdi”classifies TCM herbs as having high, moderate, or low toxicity, or as being nontoxic; in
addition, recent toxicological studies found that some chemical ingredients of the TCM herbs classified
as nontoxic can cause liver injury [181]. Likely in order to reduce toxicity of some TCM herbs, TCM
philosophy requires the use of numerous herbal TCM products as mixtures consisting of different
herbs, commonly with up to six herbs [28,185] or even more (Table 4) [185]. Typically, there is a
primary herb, referred to as the “King” [28] or “Monarch” [67] herb as the key ingredient. The other
constituents, called also “Minister”, “Assistant”, or “Envoy” [67], are believed to function as modifiers
of toxicity, which is well recognized but not detailed and not described in terms of specific molecular
toxins [28,67]; they are also considered to synergistically increase the King herb effects [185], to improve
the immune function [28], or strengthen certain aspects of not further described actions [28].
Table 5. Suspected toxic compounds implicated in liver injury from herbal TCM.
Chinese Name Scientific Name Tentative Hepatotoxic Components
Ai Ye Artemisia argyi Volatile oil
Bi Ma Zi Rhicinus communis Ricin, toxic proteins
Cang Shan Xanthium Glycosides (kaurene), diterpenoids
Chang Shan Dichor febrifuga Lour Alkaloids (dichroine)
He Huan Pi Albizia julibrissin Glycosides (saponine)
He Shou Wu Polygonum multiflorum Anthraquinones
Huang Yao Zi Discorea bulbifera L Glycosides (steroids, diosgenin), diterpenoids-lactones
Ku Lian Zi Melia azedarach Glycosides (tetranortriterpenoids)
Lei Gong Teng Tripterygium wilfordii hook F Glycosides (tripterygium), diterpenoid-lactones
Qian Li Guang Senecio scandens Pyrrolizidine alkaloids
Shan Lu Phytolacca acinosa Roxb. Alkaloids (phytolaccine)
Xiang Si Zi Abrus Precatorius Abrin
Data are adapted from reports of Ma et al. [181] and of Wu et al. [218].
7. Key Clinical Features of Liver Injury Due to TCM Herbs
Clinical features are well described in many liver injury cases, but not all reports provide
sufficient evidence of a causal relationship to the suspected TCM herb [70–179,181,182,184–190],
lacking a rigorous a method causality assessment, using a method such as RUCAM [51]. Due to these
uncertainties, clinical features presented below as examples and derived preferentially from case series
remain in part tentative.
For clinical features of liver injury caused from herbal TCM, differences are obvious between
unsaturated PA containing herbs causing HSOS and those lacking these hepatotoxins and causing
liver injury with other lesions. Therefore, results of the two groups will be presented separately, for the
HSOS group and the non HSOS group.
7.1. Duration of Herbal Use and Time to Onset
For patients with HSOS caused by Gynura segetum, the TCM also known as Shan Chi, Tu San Qi, or
under various other names, the duration of herb intake was 4–730 days with a mean of 70.2 days and a
median of 26.0 days; the latency period between start of herb use and symptoms was 5–730 days, with
a mean of 88.8 days and a median of 30.5 days [236]. These data suggest that herb use was stopped
some days before symptoms emerged, but causes of herb discontinuation use were not communicated.
This early stop is quite unusual as patients commonly stop herbal use after and not before appearance
of symptoms [236].
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It was also mentioned that liver injury due to herbal TCM develops slowly between one week and
one month [181]. Indeed, patients of the non HSOS group with liver injury by Polygonum multiflorum
showed a median time of symptom onset of 27 days with a range of 1–120 days in one study [162] or
of 30 days with a range of 1–240 days [163], while latency periods were not assessed in another study
which reported instead a mean duration of intake of 169 days with a range from 15 to 730 days [164].
A short time to onset of one day or few days puts causality in question, as it seems that the patient
started the treatment at a time when a liver disease unrelated to any herb or drug emerged, or even
worse, the treatment was considered for symptoms that were liver related but not recognized as such.
Within the non HSOS group, patients with liver injury caused by the TCM Lu Cha (green tea), who
had used this herb as extracts from two days up to more than one year and showed a time to onset in a
range from 14 days to more than one year [141]. In another study of Lu Cha, the liver injury occurred
between four days and four years; however, the time to onset was ď4 weeks in 25% and ď3 months in
70% [138].
7.2. Symptoms and Clinical Features
Whereas fluid accumulation including ascites is common in HSOS due to TCM herbs containing
PAs [122], these clinical signs are not observed in patients with liver injury caused by TCM herbs
lacking PAs. Instead, these patients experienced a variety of symptoms such as anorexia (58.0%),
fatigue (67.3%), jaundice (60.3%), nausea (35.9%), and fever (35.9%), but signs such as rash, pruritus,
and pale colored stools have also been reported [181], in support of many case reports and case
series [70–179,181,182,184–190]. Similar symptoms were described in patients with liver injury due
to non TCM herbs [50,60,89,210–216]. In more detail, liver injury by La Chu (green tea) extracts is
characterized in 19 patients by the following symptoms: Jaundice (10 cases; 52.6%), nausea (6; 31.5),
fever (6; 31.5%), fatigue (5; 26.3%), discoloration of stool and/or urine (4; 21.1%), vomiting (4; 21.1%),
malaise (4; 21.1%), pruritus, arthromyalgia, abdominal pain, and epigastric pain, each in two cases
(10.5%), as well as low back pain, hypogastric pain, right upper quadrant pain, diarrhea, asthenia,
and weight loss, each in one case (5.3%), whereby each patient had at least one symptom and most
multiple symptoms [141]. However, no information is provided for these 19 patients as to the sequence
in which the symptoms emerged [141], as opposed for instance in a patient with liver injury due
to Indian Ayurvedic herbs, who provided the following symptoms in sequence: starting with pruritus,
followed by loss of appetite, fatigue, nausea, vomiting, dark urine, light stool, and finally jaundice [50,89].
With Polygonum multiflorum as another example of liver injury not related to PAs, most of the
patients were admitted for jaundice, fatigue, anorexia, and discolored urine, shown in a report of
18 patients [162], with similar results provided in another publication [163]. Jaundice was the leading
symptom in 20/25 patients (80%) with liver injury due to Polygonum multiflorum, rarely associated with
extrahepatic manifestations such as arthralgia, fever, thrombocytopenia, pancytopenia, eosinophilia,
and skin rash [153]. It appears from these studies that patients with liver injury caused by green
tea extracts or Polygonum multiflorum were rarely monosymptomatic but mostly polysymptomatic.
Only few patients with liver injury were described as being asymptomatic [153].
Patients with HSOS present typical symptoms of abdominal distension and pain, ascites,
malaise, jaundice, hepatomegaly, and body weight increase due to ascites and edema caused by
fluid accumulation [122]. Use of TCM herbs containing PAs may result in splenic measurement at
the upper limit of normal as revealed by ultrasonography, but splenomegaly was not observed
likely due to short term use of the herbs [125]. Diagnosis of HSOS was established using the
modified Seattle criteria [122,237], and causality was proven by RUCAM. Most importantly, the
leading symptom of HSOS caused by Gynura segetum symptom is ascites, which is otherwise rarely
found in patients with liver injury by TCM herbs lacking PAs, except perhaps in end stage conditions
of liver cirrhosis. Therefore, ascites must alert the physician considering HSOS as a diagnostic option
(Table 6). Ignoring this key findings led to erroneous diagnoses and further harm to the patients, as
detailed and discussed in many reports [119–126].
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Table 6. Clinical characteristics of the hepatic sinusoidal obstructive syndrome (HSOS) caused by
Gynura segetum containing unsaturated PAs.
Conditions Results
‚ Cohort n = 116
‚ Gender
Males 57
Females 56
(NA 3)
‚ Age 17–76 years
‚ Ascites 115/116 cases
‚ Hepatomegaly 104/113 cases
‚ Jaundice 95/113 cases
‚ ALT elevation 47/60 cases
(NA 56 cases)
‚ AST elevation 50/58 cases
(NA 58 cases)
‚ Outcome
Recovery 75 cases
Chronicity 27 cases
Death 11 cases
(NA 3 cases)
Data from Gao et al., 2012 [122]. Abbreviations: ALT, Alanine aminotransferase; AST, Aspartate
aminotransferase; NA, Not available; PAs, Pyrrolizidine alkaloids.
7.3. Laboratory Results
Not all patients with liver injury by TCM herbs show LT abnormalitiess. For instance, a few
patients with HSOS had normal LT (Table 6) [120,122], low AST values of 54 U/L [129] and 79 U/L [120],
or low ALT values of 42 U/L [120]. In a larger group of patients with HSOS, ALT was 243 ˘ 60 U/L
and AST 259 ˘ 63 U/L [236]. These conditions are challenging and require clinical experience to
make an early diagnosis. Such problems are not known for the non HSOS cases of liver injury from
most other TCM herbs, because often high LT values are more frequent. For instance, increase in ALT
between 195 and 3851 U/L may be caused by green tea extracts [141] or between 601 and 3120 U/L by
Polygonum multiflorum [164] and within a similar range in another cohort [153].
Of particular interest is an analysis that describes significantly higher mean ALT values for liver
injury caused by a single TCM herb as compared to mixtures of multiple herbs (1082.9 ˘ 503.1 vs.
643.3 ˘ 530.4 U/L; p < 0.05) [238].
7.4. Severity of Liver Disease and Hy’s Law
7.4.1. Liver Adaptation
Under a treatment with TCM herbs, mild LT increases such as ALT < 5 N may be observed in 0.3%
of the patients, as shown in a large cohort of 994 patients (Table 2) [13]. These mild elevations can be
either new or pre-existing, for instance caused by a non-alcoholic or alcoholic fatty liver disease. If the
ALT elevations occurred newly and are not accompanied by increased bilirubin values or jaundice,
they are of no clinical relevance and should be interpreted as liver adaptation to the biotransformation
response of the phytochemicals. However, patients with liver adaptation progress rarely to severe
liver injury with ALT ě 5 N, increases of bilirubin or jaundice, requiring LTs monitoring during the
treatment. To be cautious, cessation of herbal TCM use should be mandatory for the patient safety,
especially if the indication is unclear and treatment was ineffective.
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7.4.2. Severe Liver Injury and Acute Liver Failure
The underlying risk factors leading to ALF are unknown [80]. Jaundice is one of the cardinal
symptoms in liver injury caused by herbal TCM [153], raising the question as to whether high bilirubin
values are risk factors of poor outcome [238] as in DILI cases [198,239]. ALF is more prevalent in
patients with HSOS caused by TCM herbs which contain PAs (Table 6) [122], but it can also occur
in connection with the use of TCM herbs not containing PAs (Table 7), as shown also in 87 Korean
patients with three fatalities and one liver transplantation [238].
Table 7. Outcome of liver injury caused by selective TCM herbs.
TCM Product/TCM Herb Fatality (n) LTX (n) Selected References with First Author
‚ Bai Xian Pi 2 Sohn, 2008 [80]
‚ Ci Wu Jia 2 Sohn, 2008 [80]
‚ Jiguja 1 Sohn, 2008 [80]
‚ Lu Cha 4 Mazzanti, 2015 [141]
‚ Ma Huang 2 Estes, 2003 [74]1 Skoulidis, 2005 [148]
‚ Polygonum multiflorum
3 Sohn, 2008 [80]
1 Jung, 2011 [153]
1 1 Wang, 2015 [164]
‚ San Chi 1 Gao, 2012 [122]
‚ Sang Hwang 11 1 Sohn, 2008 [80]
‚ Yin Chen Hao 1 Sohn, 2008 [80]
‚ Korean case series of non HSOS 3 3 Lee, 2015 [238]
LTX, Liver transplantation; HSOS, Hepatic sinusoidal obstruction syndrome; TCM, Traditional
Chinese Medicine.
In clinical practice and for risk management of these conditions, helpful recommendations derived
from Hy’s law should be followed. Indeed, the late Hyman Zimmerman stated that mortality risk of
DILI would be around 10% if jaundice appears in the course of hepatocellular injury. This statement
has been translated by the US FDA into the following three criteria: (1) serum ALT or AST > 3 N;
(2) serum total bilirubin elevated to >2 N; and (3) no other reason can be found for the combination
of increased aminotransferases and bilirubin [239]. Patients with signs of ALF (e.g., coagulopathy
and encephalopathy) should be transferred to a specialized hepatology unit. Up to now, prognostic
markers to predict the outcome and to indicate that a patient may require liver transplantation are not
evaluated in liver injury caused by TCM herbs.
7.4.3. Natural Course and Outcome
Following cessation of the herbal use, most patients with liver injury caused by herbal TCM
recovered quickly, more so when the causative herbs were free of PAs [141] as compared to herbs
containing PAs (Table 6) [122]. However, few patients continue the consumption of TCM herbs despite
symptoms, but it is not clear whether this is risky for these patients [141]. As expected, there are
no prospective studies that would evaluate whether continued use of TCM herbs despite symptoms
modifies the outcome. Continued use despite symptoms was a significant problem in patients using
isoniazid and experiencing liver injury, as the delayed cessation of the antituberculous drug was
associated with a high risk of fatality. Among 13 patients with continued INH use for more than seven
days, seven patients required a liver transplantation or died [50,240]. Conversely, continued use of
Greater Celandine in patients with symptomatic liver injury was not associated with an increased risk.
Indeed, five patients with overt symptoms, who continued treatment over a period of up to seven
months, had a favorable outcome that was contrary to clinical expectations [50,215]. Despite these
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differences of outcome depending on the causative product, intake of the herbal TCM products must
be stopped when symptoms of liver injury occur, considered this as a precautionary measure [50].
8. Biomarkers: Microsomal Epoxide Hydrolase, Pyrrole-Protein Adducts, HLA, MicroRNA,
and Metabolomics
Herbal TCM may cause a large spectrum of liver injury, affecting all cells present in the liver and
biliary tree, and ranging from mild asymptomatic liver test (LT) elevation to acute or chronic liver
injury, cirrhosis, ALF, acute and chronic cholangitis, macro- and micro-vesicular steatosis, and vascular
lesions, as provided in many reports [70–179]. However, reviewing these publications, the clinical
diagnosis of liver injury from herbal TCM in these cases remains often unclear. In fact, all authors
claimed having validly established the diagnosis and verified the causality, although in some cases
only a possible causality for the used herbal TCM product was suggested or data quality was marginal
at best. In their recent article on drug-induced liver injury and the highlights from a review of the
2015 literature, Sarges et al. [192] stated that in suspected cases of liver injury, the ability to confidently
assign causality to a particular drug, chemical, or herbal agent alone has become increasingly complex.
They recommend an exhaustive causality assessment and propose a model on which cases of possible
liver injury by drugs and herbs should be based [192], referring to published work [241,242].
8.1. Diagnostic Biomarkers
There are very few instances in which liver injury from herbal TCM is associated with specific,
mechanism-based biomarkers, which can be measured in the blood. Such mechanistic biomarkers
are presently well documented for three TCM herbs which cause intrinsic liver injury, namely the
TCM herb Shi Can (Teucrium chamaedrys, Germander) [168–176,199–201], the TCM herb San Chi
(Gynura segetum) [120–124], and the TCM Polygonum multiflorum [164]. Diagnostic biomarkers follow
specific analytical methods and can be determined in fluids such as the blood of the patients, who
experience liver injury by TCM herbs.
For Germander, specific autoantibodies are the diagnostic tools [201], and for PA containing herbs,
protein adducts and conjugates are of diagnostic value [120,122,123,129,201,236,243]. Conversely, for
Polygonum multiflorum, chemical ingredients of the plant and their metabolites provide diagnostic
information, whereby only the metabolites are classified as mechanistic biomarkers [164].
8.1.1. Established Diagnostic Biomarkers
Microsomal Epoxide Hydrolase
With anti-microsomal epoxide hydrolase autoantibodies, a most interesting and one of the
first examples of a diagnostic, mechanism-based biomarker of liver injury induced by a TCM herb
was established [201]. Primarily located at the surface of the hepatocytes, these autoantibodies
were found in the sera of patients who experienced liver injury after consumption of teas prepared
from the TCM Shi Can (Germander) for a long period of time [201]. These autoantibodies are the
diagnostic biomarkers, easily assessable in the serum of patients with such liver injury. The specificity
of these biomarkers allows attributing cases of liver injury to the ingestion of Germander, which
has been responsible for the liver injury of numerous patients [168–176,199–201]. As Germander
hepatotoxicity is reproducible in mice, the various steps leading to these antibodies have successfully
been explored [199–201]. It was early recognized that the chemical composition of Germander
comprises furan-containing neoclerodane diterpenoids. These Germander ingredients are oxidized by
CYP3A to reactive metabolites in the microsomal fraction of the hepatocytes, which corresponds to the
endoplasmatic reticulum upon electron microscopy assessment. Reactive metabolites likely interact
with the microsomal epoxide hydrolase and trigger the formation of the respective autoantibodies,
which escape from the liver into the blood. These antibodies recognize teucrin A-alkylated
epoxide hydrolase.
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Pyrrole-Protein Adducts
The second example of a diagnostic, mechanism-based biomarker of intrinsic liver injury
caused by TCM herbs relates to PA poisoning, for which a new analytical method was
established [120,122,123,129,201,236]. Using ultra performance liquid chromatography-mass
spectrometry (UPLC-MS) analysis, quantitative determination of pyrrole-protein adducts (PPAs)
in the blood of affected patients became feasible. This represents a diagnostic breakthrough and is
encouraging, as it facilitates the clinical assessment of patients with liver injury, who may or may
not have used TCM herbs containing PAs. Blood PPA concentrations were positive in all 23 patients
with HSOS caused by PA-containing TCM herbs [236]. The sensitivity of the test was 100% and the
specificity was 95.8%, while the negative predictive value was 100% and the positive likelihood ratio
was 23.81. The blood PPA levels tend to decrease quickly within 40 days and then decreased more
slowly until it was undetectable within 300 days, indicating that PA metabolites can remain in the
blood for a relatively long period of time [236].
Liver injury by PAs is a major health issue as exemplified by two TCM herbs, San Chi
(Gynura segetum), which contains PAs, and Jing Tian San (Sedum aizoon) lacking PAs, whereby San Chi
was misused in medicinal preparations instead of the nontoxic Jing Tian San [119–129,201,229–236].
Similar botanical names as well as lack of proper plant authentication and diagnostic tools created this
confusion. These problems stimulated investigations on a diagnostic biomarker of liver injury caused
by PAs and led to the development of the PAA biomarker, which is mechanism-based on the knowledge
of the reactive metabolites PAAs generated from unsaturated PAs [120,122,123,129,201,236,243].
PAAs bind covalently to DNA, albumin and other proteins, forming pyrrole-protein adducts which
enter the circulation. It seems that PAAs are generated by microsomal CYPs in the liver parenchymal
cells [120,201,229,230], but it remains unclear why toxicity occurs preferentially at another site, in the
hepatic sinusoidal endothelial cells rather than in the hepatocytes [243,244].
Unclear is also whether the low glutathione (GSH) content in the sinusoidal endothelial cells may
render these cells more susceptible to injury [243]. The functions of hepatic sinusoidal endothelial
cells have well been described [245–248], but further studies in laboratory animals may be needed in
order to clarify how PAs or PAA intermediates are transferred from the hepatocytes to the sinusoidal
endothelial cells. In animals treated with PAs, electron microscopy studies showed disruption of the
hepatocyte plasma membrane, associated with an extensive bleb formation at the sinusoidal membrane
of the hepatocytes [246]. This occurs nearby the sinusoidal endothelial cells with their well strong
endocytic activity [247]. There is also evidence that PAs undergo CYP-dependent metabolic activation
in the liver sinusoidal endothelial cells [248], suggesting that the intermediates may be generated in
these cells. Whether all these processes occur simultaneously or one by one remains to be established.
Metabolomics
For liver injury induced by Polygonum multiflorum, other diagnostic approaches were used,
classified as metabolomic biomarkers [164]. These analyze in the blood of patients with
liver injury likely caused by Polygonum multiflorum for the chemicals lysophosphatidylcholines,
phosphatidylcholines, prostagladins, fatty acids, 2,3,5,41-tetrahydroxy trans-stilbene-2-O-β-D-glucoside
(TSG), and many others. This clarifies whether a patient used this herb or a fraudulent substitute.
Analyses were done with a liquid chromatograph coupled with a high-resolution hybrid quadrupole
time-of-flight mass spectrometer (LC-QToF-MS) [164].
8.2. Progress in Developing Valid Diagnostic Biomarkers
The above discussed diagnostic biomarkers for the three TCM herbs are encouraging and
may certainly be extended to additional TCM herbs that are responsible for intrinsic liver injury.
Unquestionably, most promising are mechanistic biomarkers in order to establish the diagnosis of
liver injury related to TCM herbs, a view supported also with respect to DILI by another report [249].
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However, approaches may not be extended to idiosyncratic liver injury since its causative intermediates
are generated in small amounts in the liver cells and not prone to substantial leakage into the circulation.
In addition to the diagnostic biomarkers, there is much interest in other biomarkers not necessarily
aiming to confirm the diagnosis of advanced injury but with focus on improving early recognition of
liver injury [192,250–254], or perhaps assessing individual susceptibility [192,255,256]. Many studies
of these new biomarkers for DILI were published and discussed, but the question was raised as to
whether they really are better and what do they diagnose [249]. Critical evaluations of these studies
are needed [192,249], also in view of the flood of recent publications, shown by more than 620,000
PubMed quotations and over 40,000 more per year in the last two years [249].
8.2.1. Human Leucocyte Antigen (HLA)
Many studies relating to liver injury elucidate the role human leucocyte antigen (HLA) genotype
testing for predicting liver injury in susceptible individuals. However, it remains to be established
whether this testing is applicable to liver injury due to herbal TCM. The actual importance of
such testing in the general population remains unclear due to currently low positive and negative
predictive values of the tests [192]. With respect to DILI, characterization of genetic susceptibility by
demonstration of a strong association between a specific HLA haplotype and the liver injury has been
recently made with many drugs, including lumiracoxib, abacavir, lapatinib, antitubercular drugs, and
flucloxacillin [192,249,255].
For instance, an association was found and described in detail for lumiracoxib and HLA
DQA1*0102 [249] as well as for flucoxacillin and HLA-B*5701 [255]. Whether HLA genotypes can
be used in the future as diagnostic biomarkers, as a parameter for risk factors, or as pathogenetic
hallmarks requires further studies.
8.2.2. MicroRNA
Microarray RNA (microRNA) are short (18–25 nucleotides) noncoding RNA molecules and
function to repress specific target messenger RNAs and thereby regulate specific cellular proteins and
the phenotype of the cell [257]. There is substantial interest in the potential role of these microRNAs
for the early recognition of liver injury caused by drugs and TCM herbs in place of aminotransferases
which are considered by some as insufficiently sensitive in clinical trials of drug development and
insufficiently organ specific [192,249–254,257–260]. MicroRNA can be measured in the blood of patients
with liver injury caused by drugs such as acetaminophen (AAP) and may have a positive predictive
value in determining the outcome of AAP hepatotoxicity [192]. Such biomarkers can also be used in
determining the need for liver transplantation in AAP intoxication and were found to have a higher
sensitivity and specificity in patients with liver injury, who used AAP and received drug treatment
for HIV and tuberculosis [192,259]. Despite encouraging progress of micoRNA evaluation in liver
injury due to drugs, final recommendations for pre-clinical trials and clinical use were considered
premature [192,249]. Specific aspects of circulating microRNA molecules as biomarkers in liver
disease were also critically addressed in a recent thorough clinical review [253] and analyses of
experimental liver injury due to TCM Chuan Lian Zi (Melia Toosendan) [252] or the TCM Huan Yao Zi
(Dioscorea bulbifera) and AAP [260].
Similar restrictions as those for drugs may apply to herb induced liver injury caused by
TCM [192,252,260]. Under these conditions, some details on this subject warrant further considerations.
Basically, microRNA circulating in the blood may be found with low levels in healthy individuals
and with higher levels in patients with various diseases such as cancer, cell and organ transplantation,
coronary heart disease, stroke, sepsis, burns, or confined to specific organs [253]. Blood microRNAs can
be differentiated regarding their organ specificity, thereby allowing for instance quantitative analysis
for liver specific subtypes of microRNAs [192,249,253,257]. They originate from the injured liver,
whereby multiple mechanisms are involved in the release of microRNA from the hepatocyte such as
passive processes; e.g, simple leakage [253]. Following cell death, microRNA can reach the extracellular
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environment bound and protected by subcellular structures. Among active processes, microRNA
release via apoptotic bodies and microvesicles are known. During apoptosis, cellular microRNA is
packed into granules and subsequently into apoptotic bodies [253]. Presently, most microRNA studies
dealing with liver injury focused on drugs in both patients and animals, whereas only few reports
evaluated liver injury by TCM herbs, as assessed in animals but not in patients.
For experimental liver injury from herbal TCM, microRNAs were studied in mice using the TCM
Chuan Lian Zi (Melia Toosendan) [252]. This TCM herb is a known hepatotoxic in humans but poorly
described in the English scientific literature [82,181,252] and should be classified as a herb causing
intrinsic liver injury due to its reproducibility in animals [252]. These animal studies showed that the
TCM Chuan Lian Zi caused changes of eight microRNAs and 1723 messenger RNAs. For the eight
differentially expressed microRNAs, their predictive target genes were collected, and further analyses
revealed that several cellular functions were affected, such as cellular growth and proliferation, gene
expression, and cellular development.
All these studies show that the use of microRNA may uncover toxicological mechanisms leading
to liver injury by this TCM herb. It remains to be established whether similar findings of microRNA
are found in the blood of patients with liver injury caused by this type of herbal TCM.
In the other liver injury study that used both the TCM Huan Yao Zi (Dioscorea bulbifera) and AAP
for comparison, the microRNA profiling was different [260]. It was not studied whether this difference
applies also to other drugs or herbs. If it is confirmed, microRNA measurements could be used in
patients with liver injury to analyze the cause, synthetic drug versus herb.
Although some work including careful standardization of microRNA assays is still necessary,
serum microRNAs are promising biomarkers for assessing cases of liver injury, bearing in mind the
following points: (1) microRNAs could be a more sensitive and specific diagnostic marker of incipient
liver injury assessable prior to conventional markers such as transaminases; (2) its determination
could especially be useful in future trials with drugs and herbs including TCM herbs but studies are
still warranted to assess both idiosyncratic and intrinsic liver injury; (3) if confirmed, microRNAs’
assessment in clinical trials could assist or replace the present use of eDISH (evaluation of Drug
Induced Serious Hepatotoxicity), a software program which facilitates recognition of a liver safety
signal in clinical trials [261–264]; (4) microRNAs fingerprinting might be able to identify in a patient
with liver injury whether a specific drug or herb was responsible; and finally (5) microRNA subtypes
could elucidate possible mechanism leading to liver injury. Future studies will have to clarify these
microRNA issues, as drawing from published data any definite conclusion on the clinical use of
microRNAs would be premature.
9. Diagnostic Challenges
9.1. Minimum Quality Requirements of Herbal TCM Products
Herbal products are manufactured for human use and require quality and safety standards;
lacking these is a major issue and often communicated in several critical reports within the last
years [3,28,29,50,60,122,209,265–272]. Similar problems are evident for most herbs used in the
context of TCM [8,12,15,17,62–67,119–124,181,185,229–233], which were discussed by the Chinese
FDA, presenting details of the current status and future perspectives of the pharmacovigilance practice
and risk control of TCM drugs in China [12].
9.2. Variability of Herbal TCM Product Names, Quality, Misidentifications, Adulterants, and Impurities
The Chinese FDA provides transparency on the risks and issues of the herbal TCM, considering
many details were poorly discussed in the past [12]. The vast and diverse land area of China is a large
reservoir of TCM herbs, which contributes to the complexity of the herb species, their origins and
names, since often the same name is used for different TCM herbs or different names for the same herb.
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In addition, similar names or abbreviations for different species lead to confusion. This problem is also
documented in case narratives presented above.
Problems with the nomenclature were summarized in another report [52]. TCM clinical practice
also considers the place of origin of the TCM herbs as an important factor; some places are thought to
be superior but qualifying criteria were not provided [12].
It is recognized that differences in the growing conditions and geographical origin may influence
the chemical profiles of the TCM herbs, which may influence therapeutic efficacy and toxicity [12].
Herbal TCM product quality may be influenced by adulterations with synthetic drugs and pollution
due to contamination with pesticides, heavy metals, or radioactivity, inadequate processing procedures,
storage, solvents, solubilizers, and incorrect preparation of the TCM decoctions that relies on “the
rules of the thumb” as advised by the prescribers [12].
It is unclear, however, to what extent these quality deficits contribute to liver injury [50]. It seems
that most TCM herbal products meet quality standards. Notably, in one study in Germany, analyses
of herbal TCM products showed no quality problems [13] and in a French report of liver injury
induced by Shi Can (germander), analyses showed lack of product contamination by insecticides or
microorganisms [273].
Several other reports focused specifically on topics such as safety [3,7,8,11,13–15,25,29,59,67,164],
herbal TCM product quality [7,8,13,17,25,26,50,60,164]. TCM herb authentication by microscopy and
especially DNA barcoding [164], microbial or mycotoxin contamination [13,65,164], herbal
misidentification [50,60,122–124,164], adulterants [50,60,62,63], heavy metals [63–65,164],
pesticides [164], and other impurities [50,60]. It must be guaranteed that all TCM herbs meet
product quality standards, considering the rules of current Good Agricultural Practices (cGAPs) and
current Good Manufacturing Practices (cGMPs) (Table 8).
Table 8. Quality specifications for TCM herbs for safe use of consumers.
‚ Herbal TCM product declaration of the manufacturer with address, phone and fax number, e-mail address
‚ Expiration date of the herbal drug and herbal supplement
‚ Batch number
‚ Detailed recommendation for indication and contraindication
‚ Advice for daily dose and maximum use duration
‚ Correct labelling of all ingredients
‚ Definition of plant family, subfamily, species, subspecies, and variety
‚ Definition of plant part
‚ Definition of used solvents and solubilizers
‚ Exclusion of impurities, adulterants, and misidentifications
‚ Minimum or lack of batch to batch variability
‚ Minimum or lack of product to product variability
‚ Current Good Agricultural Practices (cGAPs)
‚ Current Good Manufacturing Practices (cGMPs)
‚ Regulatory surveillance
Details are adapted from previous reports [50,60].
9.3. Case Data Quality
Reviewing the case reports and case series of suspected liver injury induced by TCM herbs, it
is clear that the data quality of the cases is often poor [70–179,181,182,184–190]. There are, however,
suggestions on how data should be captured, presentation including narratives, and evaluation
of causality assessment can be improved [274] and which approaches should be undertaken [192].
Most promising is the prospective data acquisition at a time when liver injury is suspected, using the
items of the RUCAM and a checklist of differential diagnoses that should be excluded (Table 9) [51].
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Table 9. Checklist of differential diagnoses in cases of liver injury due to TCM herbs.
Differential Diagnosis Diagnostic Parameters
Diagnostic Exclusion
Done for Patient’s
Causality Assessment
Yes No Partial
‚ Hepatitis A virus (HAV) Anti-HAV-IgM ˝ ˝ ˝
‚ Hepatitis B virus (HBV) HBV-DNA, anti-HBc-IgM ˝ ˝ ˝
‚ Hepatitis C virus (HCV) HCV-RNA, anti-HCV ˝ ˝ ˝
‚ Hepatitis E virus (HEV) HEV-RNA , titer change for anti-HEV-IgM/anti-HEV-IgG ˝ ˝ ˝
‚ Cytomegalovirus (CMV) CMV-PCR, titer change for anti-CMV-IgM/anti-CMV-IgG ˝ ˝ ˝
‚ Epstein Barr virus (EBV) EBV-PCR, titer change for anti-EBV-IgM/anti-EBV-IgG ˝ ˝ ˝
‚ Herpes simplex virus (HSV) HSV-PCR, titer change for anti-HSV-IgM/anti-HSV-IgG ˝ ˝ ˝
‚ Varicella zoster virus (VZV) VZV-PCR, titer change for anti-VZV-IgM/anti-VZV-IgG ˝ ˝ ˝
‚ Other virus infections according to the
clinical context
Specific serology of Adenovirus, Coxsackie-B-Virus, Echovirus, Measles
virus, Rubella virus, Flavivirus, Arenavirus, Filovirus, Parvovirus, HIV,
and others
˝ ˝ ˝
‚ Other infectious diseases Specific assessment of bacteria, fungi, parasites, worms, and others ˝ ˝ ˝
‚ Autoimmune hepatitis (AIH) type I Gamma globulins, ANA, SMA, AAA, SLA/LP, Anti-LSP, Anti-ASGPR ˝ ˝ ˝
‚ Autoimmune hepatitis (AIH) type II Gamma globulins, Anti-LKM-1 (CYP 2D6), Anti-LKM-2 (CYP 2C9),Anti-LKM-3 ˝ ˝ ˝
‚ Primary biliary cholangitis (PBC) AMA, Anti PDH-E2 ˝ ˝ ˝
‚ Primary sclerosing cholangitis (PSC) p-ANCA, MRC ˝ ˝ ˝
‚ Autoimmune cholangitis (AIC) ANA, SMA ˝ ˝ ˝
‚ Overlap syndromes See AIH, PBC, PSC, and AIC ˝ ˝ ˝
‚ Non alcoholic steatohepatitis (NASH) BMI, insulin resistance, hepatomegaly, echogenicity of the liver ˝ ˝ ˝
‚ Alcoholic liver disease (ALD) Patient’s history, clinical and laboratory assessment, other alcoholicdisease(s) ˝ ˝ ˝
‚ Drug induced liver injury (DILI) or herb
induced liver injury (HILI)
Patient’s history, clinical and laboratory assessment, sonography, use of
the updated RUCAM ˝ ˝ ˝
‚ Cocaine, ecstasy and other amphetamines Toxin screening ˝ ˝ ˝
‚ Rare intoxications Toxin screening for household and occupational toxins ˝ ˝ ˝
‚ Hereditary hemochromatosis Serum ferritin, total iron-binding capacity, genotyping for C2824 andH63D mutation, hepatic iron content ˝ ˝ ˝
‚ Wilson disease
Copper excretion (24 h urine), ceruloplasmin in serum, free copper in
serum, Coombs-negative hemolytic anemia, hepatic copper content,
Kayser-Fleischer-ring, neurologic-psychiatric work-up, genotyping
˝ ˝ ˝
‚ Porphyria Porphobilinogen in urine, total porphyrines in urine ˝ ˝ ˝
‚ α1-Antitrypsin deficiency α1—Antitrypsin in serum ˝ ˝ ˝
‚ Biliary diseases Clinical and laboratory assessment, hepatobiliary sonography, MRC ˝ ˝ ˝
‚ Pancreatic diseases Clinical and laboratory assessment, sonography, CT, MRT ˝ ˝ ˝
‚ Celiac disease TTG antibodies, endomysium antibodies, duodenal biopsy ˝ ˝ ˝
‚ Anorexia nervosa Clinical context ˝ ˝ ˝
‚ Parenteral nutrition Clinical context ˝ ˝ ˝
‚ Cardiopulmonary diseases
Cardiopulmonary assessment of congestive heart disease, myocardial
infarction, cardiomyopathy, cardiac valvular dysfunction, pulmonary
embolism, pericardial diseases, arrhythmia, hemorrhagic shock, and
various other conditions
˝ ˝ ˝
‚ Addison’s disease Plasma cortisol ˝ ˝ ˝
‚ Thyroid diseases TSH basal, T4, T3 ˝ ˝ ˝
‚ Grand mal seizures Clinical context of epileptic seizure (duration > 30 min) ˝ ˝ ˝
‚ Heat stroke Shock, hyperthermia ˝ ˝ ˝
‚ Polytrauma Shock, liver injury ˝ ˝ ˝
‚ Systemic diseases Specific assessment of sarcoidosis, amyloidosis, metastatic tumor, sepsis,and others ˝ ˝ ˝
‚ Other diseases Clinical context ˝ ˝ ˝
This tabular listing is derived from a previous publication [51]. Although not comprehensive,
it is to be used as a guide and in connection with RUCAM [51]. AAA, Anti-actin antibodies; AMA,
Antimitochondrial antibodies; ANA, Antinuclear antibodies; ASGPR, Asialo-glycoprotein-receptor;
BMI, Body mass index; CT, Computed tomography; CYP, Cytochrome P450; DPH, Pyruvate
dehydrogenase; HAV, Hepatitis A virus; HBc, Hepatitis B core; HBV, Hepatitis B virus; HCV, Hepatitis
C virus; HEV, Hepatitis E virus; HILI, Herb induced liver injury; HIV; human immunodeficiency
virus; LKM, Liver kidney microsomes; LP, Liver-pancreas antigen; LSP, Liver specific protein; MRC,
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Magnetic resonance cholangiography; MRT, Magnetic resonance tomography; p-ANCA, Perinuclear
antineutrophil cytoplasmatic antibodies; PCR, Polymerase chain reaction; RUCAM, Roussel Uclaf
Causality Assessment Method; SLA, Soluble liver antigen; SMA, Smooth muscle antibodies; TSH,
Thyroid stimulating hormone; TTG, Tissue transglutaminase.
10. Hepatotoxicity Criteria and Liver Injury Pattern
Criteria of liver injury and liver injury pattern are essential for case assessment of suspected liver
injury caused by TCM herbs (Figure 4).
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The overall accepted definitions of liver injury and the liver injury pattern (Figure 4) goes back to
when RUCAM was developed in 1993 [275,276] and has remained unchanged except for one criterion
which was changed to ALT > 5 N [51]. These definitions can be applied to suspected liver injury caused
not only by TCM herbs, but also by other herbs and drugs (Figure 4). Hepatocellular injury prevails in
most TCM related case series [164,181,238].
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11. RUCAM as the Preferred Method to Assess Causality in Liver Injury Caused by TCM Herbs
Causality for TCM herbs in patients with suspected liver injury is best assessed with RUCAM
in the version updated in 2016 [15] and based on the original version [275,276]. Assessment requires
to determine the type of injury: hepatocellular type or cholestatic or mixed type (Figure 3) [51].
RUCAM represents a structured, standardized, validated, and hepatotoxicity specific diagnostic
approach, which attributes scores to key items that reflect the natural course of the liver injury, ALT
dechallenge features, and search for alternative causes [51].
RUCAM pays special attention to all core elements that are relevant to liver injury caused by TCM
herbs, as described in detail [15]. In short, the key items are assessed in seven domains: (1) the time
to onset from the beginning of the herb intake, with specific criteria that are well scored and clearly
defined with a time frame between beginning of the herb use with day 0 as the first day of intake and
the onset of increased LTs or symptoms; (2) precise dechallenge criteria with scores reflecting the natural
course of LTs after cessation of the suspected herb are cornerstones of RUCAM, while treatment during
the dechallenge phase with drugs such as steroids or ursodesoxycholic acid may mask the natural
course and allows only a score of 0, reflecting no information; (3) risk factors such as current alcohol
use and age are to be considered; (4) concomitant use of drugs and herbs is a crucial item, requiring
details of a temporal association and potential hepatotoxic features of the used product and a separate
evaluation; (5) the search for alternative causes considers the clinically most relevant causes such as
infections by HAV, HBV, HCV, HEV, CMV, EBV, HSV, and VZV, to be assessed by parameters such as
PCR and IgM/IgG antibody titers also upon repetitive analyses, as well as complications of underlying
disease(s); (6) previous hepatotoxicity listed in the product information sheet (e.g., Summary of product
characteristics in the EU or product information in the US) must be checked; and finally (7) the response
to any unintentional reexposure has to be evaluated, as to whether specific criteria of a positive test
result are fulfilled. Items of these seven domains provide individual scores for each suspected TCM
herb in a case report, giving a final quantitative grading of causality: ď0, excluded; 1–2, unlikely; 3–5,
possible; 6–8, probable; ě9, highly probable [51]. However, RUCAM based assessment should not
be limited to providing the final score. Instead, for reasons of transparency and reassessment, each
item with its score for any TCM herb and concomitant product must be presented [274], not only to
regulatory agencies and the manufacturer but also and more importantly to editors if a publication
as a case report or case series is considered. Lacking presentation of individual RUCAM based data
would invalidate such publications.
This scoring system of RUCAM is unique and meets the requirements of clinicians and
practitioners in care for their patients with suspected liver injury caused by TCM herbs, assisting to
establish the timely diagnosis with a high degree of certainty. RUCAM is user-friendly as there is no
need of discussions among experts, who are not always available when their opinion is requested.
RUCAM is the most commonly used causality assessment method for injury cases worldwide
and is also intensively used in the Asian region [51] including China where it is applied and
recommended [51,277]. RUCAM has many advantages compared to other methods attempting
to assess such causality (Table 10) [51].
Medicines 2016, 3, 18 41 of 60
Table 10. Core elements of RUCAM as compared to other causality methods
Items RUCAM MV DILIN Naranjo WHO AD HOC
‚ Time frame of latency period (score) + + 0 0 0 0
‚ Time frame of dechallenge (score) + + 0 0 0 0
‚ Recurrent ALT or ALP increase (score) + 0 0 0 0 0
‚ Definition of risk factors (score) + 0 0 0 0 0
‚ All comedications (score) + 0 0 + 0 0
‚ Individual comedication (score) + 0 0 0 0
‚ Search for individual alternative causes (score) + + 0 0 0 0
‚ Verified exclusion of specific alternative causes (score) + + 0 0 0 0
‚ All specifically assessed HAV, HBV, HCV, HEV (score) + 0 0 0 0 0
‚ All specifically assessed CMV, EBV, HSV, VZV (score) + 0 0 0 0 0
‚ Evaluation of cardiac hepatopathy (score) + + 0 0 0 0
‚ Liver and biliary tract imaging (score) + 0 0 0 0 0
‚ Color Doppler sonography of liver vessels (score) + 0 0 0 0 0
‚ Prior known hepatotoxicity (score) + + 0 + 0 0
‚ Search for unintended reexposure (score) + + 0 + 0 0
‚ Definition of unintended reexposure (score) + 0 0 0 0 0
‚ Qualified criteria of unintended reexposure (score) + 0 0 0 0 0
‚ Laboratory hepatotoxicity criteria + + + 0 0 0
‚ Laboratory hepatotoxicity pattern + + + 0 0 0
‚ Hepatotoxicity specific method + + + 0 0 0
‚ Structured, liver related method + + 0 0 0 0
‚ Quantitative, liver related method + + 0 0 0 0
‚ Validated method (gold standard) + 0 0 0 0 0
Adapted from a previous report, which provides additional information as well as references for RUCAM and
the other methods [51]. RUCAM, Roussel Uclaf Causality Assessment Method; MV, Maria & Victorino method;
DILIN, Drug-Induced Liver Injury Network method, WHO method, WHO global introspection method. The
symbol + shows that this specific item is published, and the symbol 0 indicate lacking publication. ALT: Alanine
aminotransferase; ALP: Alkaline phosphatase; CMV: Cytomegalovirus; EBV: Epstein Barr virus; HAV: Hepatitis
A virus; HBV: Hepatitis B virus; HCV: Hepatitis C virus; HEV: Hepatitis E virus; HSV: Herpes simplex virus;
VZV: Varicella zoster virus.
In many countries and for more than two decades, physicians, experts in clinical hepatotoxicity,
international registries, regulatory agencies, published case reports, and pharmaceutical companies
successfully applied RUCAM for suspected liver injury, with increasing tendency [51]. RUCAM was
also often applied in cases of liver injury caused by TCM herbs (Table 11) [80,82,104,105,110–113,120,
122,134,138,151,162,164,165,186,221,278–280].
RUCAM is rarely used in the United States (Tables 11 and 12), where the DILIN method is
preferred, which circumvents scoring of individual items and obviates transparency (Table 10) [51] as
shown also in a recent report of seven cases with suspected liver injury [281]. In this study, RUCAM
causality levels were low with unlikely in one case, possible in four cases, and probable in two cases
only; conversely, the DILIN method attributed a probable or higher causality to six cases and a possible
causality to one case. Case evaluations were confounded by an undefined reexposure test, several
comedications, as 5/7 patients (71.4%) used up to two other prescription medications or herbal dietary
supplements, and preexisting chronic HBV infection, which caused liver cirrhosis, requiring a liver
transplant. The suggestion that DILI may have superimposed on chronic HBV infection [281] appears
unlikely in view of clinical experience and a previous analysis [198].
Also, it appears that only part of the requested alternative virus infections such as HSV and VZV
was excluded, which creates problems as any diagnosis of organ injury is a diagnosis of exclusion, not
fulfilled in this report [281]. Even more problematic was the approach to exclude HEV, as assessment
was confounded by positive anti-HEV IgG titers, incomplete analysis of essential HEV parameters,
and not prospective evaluations. HEV-RNA was not at all determined in any of the cases for unknown
reasons, and the used HEV antibody assays were not specified [281], disregarding the well-known
problem of lacking FDA approval [241,242,282]. For none of these seven patients, product use
or purchase was confirmed, nor was a product analysis done. Suggestions how to provide good
evaluations of case data were made recently by scientists from the USA [192]. Their recommendations
should be followed in the future.
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Table 11. Listing of selected individual reports using RUCAM in suspected cases of liver injury caused
by TCM herbs, updated and adapted from a previous report [51]. DILI, drug induced liver injury; HILI,
herb induced liver injury; TCM, traditional Chinese medicine.
Cases Products Country/Region Year First Author
HILI Ji Xue Cao Argentina/South America 2005 Jorge [112]
HILI Lu Cha (Green tea , Camellia sinensis) France/Europe 2005 Gloro [278]
HILI Bo He, Chuan Lian Zi, and various other herbal TCM Korea/Asia 2006 Yuen [82]
HILI Lu Cha Spain/Europe 2006 Jimenez-Saenz [134]
HILI Polygonum multiflorum Columbia/South America 2006 Cárdenas [151]
HILI Bai Xian Pi, Kudzu, Lu Cha, Yin Chen Hao Korea/Asia 2008 Kang [111]
HILI Bai Xian Pi, Ci Wu Jia, Shou Wu Pian, Yin Chen Hao Korea/Asia 2008 Sohn [80]
HIL Polygonum multiflorum China/Asia 2009 Zhang [161]
HILI Lu Cha Italy/Europe 2009 Mazzanti [138]
HILI Corydalis speciosa Korea/Asia 2009 Kang [111]
HILI Ge Gen Korea/Asia 2009 Kim [104]
HILI Ho Shou Wu Korea/Asia 2010 Bae [105]
HILI Aloe Korea/Asia 2010 Yang [279]
HIL Polygonum multiflorum Korea/Asia 2011 Jung [153]
HILI Gynura segetum Hong Kong/Asia 2011 Lin [120]
HILI Juguju Korea/Asia 2012 Kim [113]
HILI Gynura segetum Hong Kong/Asia 2012 Gao [122]
HILI DILI Multiple herbs synthetic drugs and Korea/Asia 2012 Suk [182]
DILI HILI Multiple TCM herbs and synthetic drugs China/Asia 2014 Hao [186]
HILI Polygonum multiflorum China/Asia 2014 Dong [162]
HILI Lu Cha Italy/Europe 2015 Mazzanti [221]
HILI Polygonum multiflorum China/Asia 2015 Lei [163]
HILI Polygonum multiflorum China/Asia 2015 Wang [164]
HILI Polygonum multiforme China/Asia 2015 Zhu [187]
HILI Single TCM herbs Germany/Europe 2016 Douros [183]
HILI DILI Multiple TCM herbs, synthetic drugs Korea/Asia 2016 Woo [280]
HILI Chinese skullcap, black catechu USA 2016 Papafragkakis [110]
HILI Various TCM herbs Germany/Europe 2016 Melchart [14]
Table 12. Listing of selected international registries and regulatory agencies, and associated groups
that applied RUCAM in suspected cases of liver injury due to TCM herbs.
Cases Suspected Products Country/Region Year First Author of the Group/Agency
HILI DILI Various herbal TCM, synthetic drugs Singapore/Asia 2006 Wai [283], National University of Singapore
HILI Lu Cha Sweden/Europe 2007 Björnsson [284], Swedish Adverse Drug ReactionsAdvisory Committee
HILI Lu Cha, other TCM herbs Spain/Europe 2008 García-Cortés [136], Spanish Liver Toxicity Registry
HILI DILI Few TCM herbs, multiple drugs Spain/Europe 2008 García-Cortés [285], Spanish Group for the Study ofDrug-induced Liver Disease
HILI Various TCM herbs Hong Kong 2011 Chau [286], Hong Kong Herb-Induced Liver InjuryNetwork (HK-HILIN), Hong Kong
HILI Polygonum multiflorum Korea/Asia 2011
Jung [153], School of Medicine, Changwon
Gyeongsang National University School of Medicine,
Jinju/Sungkyunkwan University
Several international registries and regulatory agencies applied RUCAM for causality assessment
in liver injury caused by TCM herbs (Table 12) [136,153,283–286].
12. Reexposure
One way to firmly establish the diagnosis of an initially suspected liver injury by TCM herbs is by
using positive test results if these are available [51]. Intentional reexposure tests are obsolete due to
the high health risk for the patient. Case reports and case series of suspected liver injury caused by
various TCM herbs, other herbs and herbal dietary supplements may contain the information that in
one or the other patient a positive reexposure test was found. In most reports, however, details of the
results were not provided and did not allow a valid conclusion. For instance, among 53 cases with liver
injury, a positive reexposure test was reported in eight patients, but the reanalysis of these published
reexposure tests with claimed positive results was disappointing, since in only one case out of these
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eight cases a positive test result could be verified; in another case, the test result was clearly negative,
while in the remaining six cases, data were considered as uninterpretable due to missing information
to comply adequately with specific criteria [287]. In these eight cases, causality reassessment with
RUCAM revealed causality levels of probable in one case and of unlikely and excluded in four and
three cases, respectively [287]. Therefore, both RUCAM and unintentional reexposure tests are valuable
tools to assess causality [287], while similar and confirmatory results were subsequently published
with RUCAM [288].
Similarly, in 25 cases of suspected liver injury caused by TCM herbs, the authors claimed a
positive reexposure test result; however, this result was confirmed upon reassessment in only 14 cases
using a criteria based approach, while the reevaluation in the remaining nine patients provided either
negative or uninterpretable test results [180]. For future cases of reported positive reexposure tests,
special attention should be paid, as to whether specific criteria were such as those published recently in
connection with details of RUCAM [51]. To circumvent inappropriate claims that a positive reexposure
test could have established causality in liver injury cases, it is of importance to present details of such
reexposure. For a positive reexposure test result, several criteria must be fulfilled (Table 13) [51].
Table 13. Conditions of unintentional reexposure tests in cases of liver injury caused by TCM herbs.
Reexposure Test Result
Hepatocellular Injury Cholestatic or Mixed Liver Injury
ALTb ALTr ALPb ALPr
‚ Positive <5 N ě2 ALTb <2 N ě2 ALPb
‚ Negative <5 N <2 ALTb <2 N <2 ALPb
‚ Negative ě5 N ě2 ALTb ě2 N ě2 ALPb
‚ Negative ě5 N <2 ALTb ě2 N <2 ALPb
‚ Uninterpretable <5 N n.a. <2 N n.a.
‚ Uninterpretable n.a. ě2 ALTb n.a. ě2 ALPb
‚ Uninterpretable n.a. n.a. n.a. n.a.
Conditions and criteria for an unintentional reexposure test are described in a previous report [51].
Accordingly, required data for the hepatocellular injury are the ALT levels just before reexposure, referred to
as baseline ALT or ALTb, and the ALT levels during reexposure, referred to as ALTr. Response to reexposure
is positive, if both criteria are met: first, ALTb is below 5 N with N as the upper limit of the normal value,
and second, after reexposure, ALT should increase to at least twice the baseline ALT value (ALTr ě2 ALTb).
Other variations are evaluated as negative or uninterpretable results. For the cholestatic or mixed liver injury,
corresponding values of ALP are to be used instead of ALT. Abbreviations: ALP, Alkaline phosphatase; ALT,
Alanine aminotransferase; HILI, Herb induced liver injury; N, Upper limit of Normal; n.a., not available.
13. TCM Herbs with Established, Questionable, or Lacking Liver Injury and Listing Compilation
Many publications reporting cases of liver injury caused by TCM herbs used RUCAM to assess
causality (Tables 11 and 12) and provided RUCAM based causality levels, which varied from highly
probable to unlikely or excluded [80,82,104,105,110–113,120,122,134,136,138,151,153,162,164,165,186,
221,278–280,283–286]. Often, only final RUCAM scores were presented and no case details that
precluded subsequent reassessment. Nevertheless, these publications are important as they may give
some impression of the tentative number of patients involved and the causality grading. The difficulties
to arrive at a valid causality determination in liver injury cases may be illustrated with the example of
two TCM herbs, Polygonum multiflorum and Lu Cha (green tea).
With respect to Polygonum multiflorum, substantial progress has been made to clarify to what
extent liver injury is caused by this TCM herb. This topic was mostly approached in case series of
suspected liver injury from Polygonum multiflorum, but specific causality assessment was either
lacking or fragmentary [150,153,161–164]. The first review of a case series goes back to 2009, when
Zhang et al. [161] reported in a Chinese medical journal on 24 liver injury cases from
Polygonum multiflorum, which were retrieved from the scientific literature published between 1978 and
2008 but were not submitted to a regular causality assessment method. In 2015 and again without
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any use of a causality assessment method, data on 450 patients with suspected liver injury caused by
Polygonum multiflorum were reported by Lei et al. [163]. In these two studies [161,163], clinical features
of suspected liver injury from Polygonum multiflorum were carefully analyzed and presented, but in
face of a lacking formal causality assessment the obtained data must be considered as vague, unless
causality will now be done as expected from the scientific community.
The breakthrough came in 2011, when the RUCAM based report by Jung et al. [153] expanded
our knowledge on this topic and provided details of 25 cases with a probable causality in 15 patients
and a highly probable causality in 10 patients. RUCAM was also used in two other studies that
were published in 2014 [162,164]. Dong et al. [162] reported the results of 18 patients with liver
injury following ingestion of Polygonum multiflorum. Upon RUCAM based causality assessment,
14/18 patients (77.8%) reached a highly probable causality, with four patients (22.2%) who achieved a
probable causality level. Such high causality levels are likely due to the strict inclusion criteria which
led to exclusion of all patients who were comedicated with any other herb or drug. Primarily excluded
were also patients with any virus infection.
In addition, Wang et al. [67] reassessed published cases of liver injury from Polygonum multiflorum
and found in only 45/147 cases (30.6%) a highly probable causality by RUCAM criteria, whereas
the assessment of 40 own hospitalized cases revealed a figure of 22.5% (9/40 cases). For the
hospitalized group, proposals involving pharmacognosy, phytochemistry, and metabolomics tests
were made to improve causality levels, but these techniques are not routinely available at other centers.
Zhu et al. [187] also used RUCAM in another study of liver injury caused by Polygonum multiflorum
and found that of 158 liver injury patients, who used Polygonum multiflorum preparations, 92 (58.2%)
combined with Western medicine or Chinese herbal preparations without Polygonum multiflorum.
Lu Cha (Camellia sinensis, green tea) or more specifically green tea extracts (GTE) and their potential
hepatotoxicity was for the US Pharmacopeia (USP) an early regulatory matter [137], which would
have been best solved with the use of a liver specific causality assessment method such as RUCAM.
Instead and in line with the disputed approach for another herb namely black cohosh [265,289,290],
USP again used for the suspected cases of liver injury from GTE the Naranjo method [137] with its
known problematic lack of liver specific characteristics [265,290,291], as opposed to the liver specific
RUCAM (Table 10). The USP approach led to uniformly possible causality levels for all evaluated
cases [137]. Such uniformity is unusual and signifies a low discriminating power of the used method.
Indeed, the Naranjo scale was considered by Liss and Lewis [291] as too sensitive, allowing a possible
causality even in the absence of essential data or by virtue of the patient simply having taken the
suspected agent, and concern has been expressed that a more sophisticated judgment would have been
expected from the USP. In a clinical context, such low causality levels are usually of little relevance.
Assessing the GTE cases, USP correctly acknowledged the limitations of dietary supplement
adverse event reports, most of which contain incomplete information or confounding variables [137].
However, recognizing the need for consistent evaluation using reliable causality scales, USP adopted
as a means of achieving consistency in evaluations and minimizing biases through the use of a
validated causality scale. Notably, the Naranjo scale has never been validated for liver injury cases,
which should have excluded the use of the Naranjo scale for the USP assessment. Another statement
of the USP is not founded, that the facility of the Naranjo scale to accommodate the limitations
of missing data was considered a further bonus [137]. The limitations of the Naranjo scale were
summarized recently, which was designed for evaluation of toxic drug reactions and contains questions
regarding drug concentrations and monitoring, dose relationship, including decreasing dose, placebo
response, cross-reactivity, and confirmation of the adverse drug reaction using unidentified objective
evidence [290].
Attempts of the USP Dietary Supplements Information Expert Committee (DSI EC) are underway
to more critically reevaluate the GTE cases. It is hoped that RUCAM will then be used and the
reexposure test criteria are carefully applied by the experts in order to overcome prior shortcomings.
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Subsequent RUCAM based assessments showed that causality could be validly established for only
part of the GTE cases [138,140,141].
Of note, a placebo-controlled parallel study to evaluate the chronic effects of GTE given before
meals on LTs showed no negative effects on LTs when used for three weeks [220]. This time frame may
be too short to allow a final conclusion since GTE was used partially much longer by patients who
experienced liver injury [141]. As fasting increases the intestinal absorption of GTE catechins [140], this
condition may have prevailed in the clinical cases and could have not been considered appropriately
in the GTE study [220].
Going back to the majority of TCM herbs and considering published cases of suspected liver
injury that were evaluated for causality by RUCAM, positive reexposure tests meeting specific criteria,
or both, it appears that many TCM herbs may be potentially hepatotoxic, sometimes confined to a very
small group of cases (Table 14) [50,138,180,188,221,292].
Table 14. Causality assessment by RUCAM and/or positive reexposure tests in cases with assumed
liver injury due to selected herbal Traditional Chinese Medicine (TCM) products.
Herbal TCM RUCAM Based Causality Reexposure Based Causality
‚ Aconitum carmichaeli + ´
‚ Bai Xian Pi + ´
‚ Bo He + ´
‚ Cassia obtusifolia + ´
‚ Ci Wu Jia + ´
‚ Chuan Lian Zi + ´
‚ Corydalis yanhusuo + ´
‚ Da Huang + ´
‚ Gan Cao + ´
‚ Ge Gen + ´
‚ Ho Shou Wu + ´
‚ Huang Qin ´ ´
‚ Hwang Geun Cho ´ +
‚ Ji Gu Cao ´ +
‚ Ji Xue Cao ´ ´
‚ Jin Bu Huan + +
‚ Jue Ming Zi + ´
‚ Jiguja + ´
‚ Kudzu ´ ´
‚ Ling Yang Qing Fei Keli + ´
‚ Lu Cha + +
‚ Ma Huang ´ +
‚ Polygonum multiflorum + +
‚ Psoralea corylifolia + ´
‚ Rhen Shen + ´
‚ Rheum officinale + ´
‚ Shou Wu Pian + +
‚ Shan Chi + ´
‚ Shen Min + ´
‚ Syo Saiko To + +
‚ Xiao Chai Hu Tang ´ +
‚ Zexie + ´
‚ Zhen Chu Cao + ´
RUCAM: Roussel Uclaf Causality Assessment Method. + represents causality was confirmed, - indicates that
causality was not confirmed.
For few TCM herbs, initial claims of their hepatotoxic potency have to be questioned. For instance,
it is now clear that the TCM Sedum aizoon lacks hepatotoxicity, as hepatotoxic PAs are not
ingredients [120]. Similarly, there is also lack of convincing evidence that the TCM Ba Jiao Lian
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(Dysosma pleianthum) is hepatotoxic, as assumed previously [53,71–73] and outlined for this TCM
under Narratives above.
14. Chronic Courses and Injury Risk from TCM Herbs for Preexisting Liver Disease
As for DILI, some authors suggested that liver injury from TCM herbs may cause chronic sequalae,
but this is not yet sufficiently established, especially in countries with a high prevalence of chronic HBV
and HCV infections; these infections must be considered as confounders, unless they were excluded
with a high grade of certainty. Conditions are clearly different in cases of HSOS from PAs that damage
sinusoidal endothelial cells without chances of complete restoration (Table 6) [122].
The relationship between TCM herbs and pre-existing liver disease is complex particularly when
increased LTs or new symptoms emerge in patients with pre-existing liver disease during herbal TCM
use. This requires two strategies to assess whether these changes are due to liver injury from the TCM
herb as a new event or to flares of the underlying liver disease. Lacking a valid diagnostic biomarker,
liver injury from TCM herbs is a diagnosis of exclusion and requires causality assessment by RUCAM.
Flares of pre-existing liver disease can reliably be assessed in some hepatotropic virus infections by
polymerase chain reaction (PCR) and antibody titers at the beginning and in the clinical course to
ascertain flares during the natural course of the disease. Unfortunately, flares cannot be verified in many
other liver diseases such as alcoholic liver disease, since specific tests are unavailable. However, such a
diagnostic approach using RUCAM and biological markers of pre-existing liver diseases and would
determine whether TCM herbs or underlying liver diseases caused the LT abnormalities or the new
symptoms. More importantly, a clear diagnosis is essential to ensure effective disease management by
cessation of the suspected herb. Similar considerations apply to DILI [198].
15. Comparison with Drug Induced Liver Injury
A recent study evaluated characteristics of liver injuries from TCM herbs as compared to those
from Western drugs in overall 1985 cases following causality assessment by RUCAM [188]. In this
analysis, 870 patients (43.8%) used Western medicine, 563 patients (28.4%) took TCM herbs, while
552 patients (27.8%) coadministered Western medicine and TCM herbs. Peak ALT values as expressed
as means were similar in the Western medicine group as compared to the TCM herb group and did not
allow an ALT based differentiation. Prognosis with good outcome was similar in the two groups, with
a marginally higher fatality rate in the TCM herb group and a marginally higher transplantation rate in
the Western medicine group. The most commonly implicated TCM herbs were Polygonum multiflorum,
Psoralea corylifolia, Corydalis yanhusuo, Rheum officinale, Cassia obtusifolia, and Aconitum carmichaeli [188],
all of which had a high casualty level as established by RUCAM and were listed under the TCM herbs
with confirmed causality (Table 4). In another article based on data of patients with ALF or acute
liver injury in 32 academic centers in the US, the comparison of the severity between DILI and HILI
including complementary medicines and dietary supplements showed that the HILI group had a
higher rate of transplantation and lower transplant-free survival in those who progressed to ALF [293].
16. Outbreaks of Liver Injury from TCM Herbs
Several publications report liver injury outbreaks related to consumption of food contaminated by
plants, which contain unsaturated PAs and are also in use as TCM herbs in mainland China [294–297].
For example, following a two-year period of severe drought, a very large number of patients with
massive ascites and emaciation were observed in northwestern Afghanistan [294]. Clinico-pathological
studies showed that these were typical cases of HSOS. The outbreak was caused by consumption of
bread made from wheat contaminated with seeds of Heliotropium plants, which were shown to contain
PAs. Examination of 7200 inhabitants from the affected villages showed evidence of liver disease in
22.8%. Clinical improvement was observed in thirteen cases after three to nine months, and in three
cases liver biopsies showed almost complete disappearance of initial abnormalities [294]. A more
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recent outbreak of HSOS was reported from Western Afghanistan, associated with exposure to wheat
flour contaminated with PAs, but the incriminating plant remained unclear [295].
Two other outbreaks of HSOS were reported from India [296,297]. One of these was probably
caused by consumption of cereals mixed with seeds of a plant (Crotalaria sp.) containing PAs, which
occurred in the Sarguja district of India end of 1976; of the 67 recorded cases, 42% died [296]. The HSOS
outbreaks were also highlighted in a recent systematic review article [298].
17. Conclusions
TCM herbs are highly appreciated around the world and easily accessible via the internet and
thus can escape regulatory surveillance which is often not well established in many countries for this
herbal TCM. Concomitantly, liver injury from TCM herbs emerges as a clinical problem and can evolve
into acute liver failure in rare cases. Clinical signs are often non-specific, and there is no diagnostic
feature in most cases that delineates liver injury due to herbal TCM from alternative causes of liver
disease. Therefore, the diagnosis of liver injury induced by TCM herbs is a diagnosis of exclusion,
for which RUCAM can aid the clinician to establish causality. Liver injury from herbal TCM is rare
and similarly to drugs can be caused by an unpredictable idiosyncratic or a predictable intrinsic
toxicity. Clinical features of liver injury from herbal TCM are variable. Specific diagnostic biomarkers
such as microsomal epoxide hydrolase, pyrrole-protein adducts, metabolomics, and microRNA are
available for only a few hepatotoxic TCM herbs. The diagnosis is ascertained if alternative causes
are validly excluded and causality levels of probable or highly probable are achieved applying the
liver specific RUCAM as the most commonly used diagnostic tool worldwide. Case evaluation
may be confounded by inappropriate or lacking causality assessments, poor herbal product quality,
insufficiently documented cases, and neglecting exclusion of alternative causes such as infections
by hepatotropic viruses including hepatitis E virus. Herbal TCM used as medicine should be under
stricter regulatory surveillance, considering these products as herbal drugs. Finally, clinical studies to
evaluate the benefit/risk balance of herbal drugs should be encouraged.
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